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A B S T R A C T
Background
Malaria is an important cause of morbidity and mortality, in particular among children and pregnant women in sub-Saharan Africa.
Prompt access to diagnosis and treatment with effective antimalarial drugs is a central component of the World Health Organization’s
(WHO) strategy for malaria control. Home- or community-based programmes for managing malaria are one strategy that has been
proposed to overcome the geographical barrier to malaria treatment.
Objectives
To evaluate home- and community-based management strategies for treating malaria.
Search methods
We searched the Cochrane Central Register of Controlled Trials published in The Cochrane Library; MEDLINE; EMBASE; Science
Citation Index; PsycINFO/LIT; CINAHL; WHO clinical trial registry platform; and the metaRegister of Controlled Trials up to
September 2012.
Selection criteria
Randomized controlled trials (RCTs) and non-RCTs that evaluated the effects of a home- or community-based programme for treating
malaria in a malaria endemic setting.
Data collection and analysis
Two authors independently screened and selected studies, extracted data, and assessed the risk of bias. Where possible the effects of
interventions are compared using risk ratios (RR), and presented with 95% confidence intervals (CI). The quality of the evidence was
assessed using the GRADE approach.
Main results
We identified 10 trials that met the inclusion criteria. The interventions involved brief training of basic-level health workers or mothers,
and most provided the antimalarial for free or at a highly subsidized cost. In eight of the studies, fevers were treated presumptively
without parasitological confirmation with microscopy or a rapid diagnostic test (RDT). Two studies trained community health workers
to use RDTs as a component of community management of fever.
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Home- or community-based strategies probably increase the number of people with fever who receive an appropriate antimalarial
within 24 hours (RR 2.27, 95% CI 1.79 to 2.88 in one trial; RR 9.79, 95% CI 6.87 to 13.95 in a second trial; 3099 participants,
moderate quality evidence). They may also reduce all-cause mortality, but to date this has only been demonstrated in rural Ethiopia (RR
0.58, 95% CI 0.44 to 0.77, one trial, 13,677 participants, moderate quality evidence).
Hospital admissions in children were reported in one small trial from urban Uganda, with no effect detected (437 participants, very
low quality evidence). No studies reported on severe malaria. For parasitaemia prevalence, the study from urban Uganda demonstrated a
reduction in community parasite prevalence (RR 0.22, 95%CI 0.08 to 0.64, 365 participants), but a second study in rural Burkina Faso
did not (1006 participants). Home- or community-based programmes may have little or no effect on the prevalence of anaemia (three
trials, 3612 participants, low quality evidence). None of the included studies reported on adverse effects of using home- or community-
based programmes for treating malaria.
In two studieswhich trained community healthworkers to only prescribe antimalarials after a positiveRDT, prescriptions of antimalarials
were reduced compared to the control group where community health workers used clinical diagnosis (RR 0.39, 95% CI 0.18 to 0.84,
two trials, 5944 participants, moderate quality evidence). In these two studies, mortality and hospitalizations remained very low in both
groups despite the lower use of antimalarials (two trials, 5977 participants, low quality evidence).
Authors’ conclusions
Home- or community-based interventions which provide antimalarial drugs free of charge probably improve prompt access to anti-
malarials, and there is moderate quality evidence from rural Ethiopia that they may impact on childhood mortality when implemented
in appropriate settings.
Programmes which treat all fevers presumptively with antimalarials lead to overuse antimalarials, and potentially undertreat other causes
of fever such as pneumonia. Incorporating RDT diagnosis into home- or community-based programmes for malaria may help to reduce
this overuse of antimalarials, and has been shown to be safe under trial conditions.
P L A I N L A N G U A G E S U M M A R Y
Home- or community-based programmes for treating malaria
Malaria is an important cause of death especially in children and pregnant women living in sub-Saharan Africa. In many rural areas,
children are unable to access effective malaria treatment because health services are either too far away or antimalarial drugs are too
expensive. Home- or community-based programmes for managing malaria have been proposed as a key strategy to overcome these
problems. In these programmes people living in rural settings, such as mothers, volunteers, or community health workers, are trained
to recognise fever and provide antimalarial medicines at a low cost or for free. Malaria is not the only cause of fever and recently rapid
diagnostic tests (RDTs) have become available. They are easy to use and enable trained workers to more accurately diagnose malaria
and refer sick children without malaria for care elsewhere.
We examined the research published up to 12 September 2012 and we identified 10 studies for inclusion in this systematic review. In
eight studies all people with fever were treated with antimalarial drugs by community health workers and in two studies community
health workers were trained to confirm malaria in people using RDTs.
Home- or community-based strategies probably increase the number of people with fever that receive an effective antimalarial within
24 hours (moderate quality evidence). They probably reduce the number of deaths in areas where malaria is common and there is poor
access to health services (moderate quality evidence) but to date this has only been demonstrated in one study from a rural setting in
Ethiopia. We do not know whether they reduce the number of people requiring admission to hospital (very low quality evidence), or the
number of people with evidence of malaria infection in their blood (very low quality evidence). Home- or community-based programmes
may have little or no effect on the number of people with anaemia (low quality evidence). None of the included studies reported on
adverse effects of using home- or community-based programmes for treating malaria.
Use of RDTs instead of clinical diagnosis in home- or community-based programmes for treating malaria probably reduces the overuse
of antimalarials drugs (moderate quality evidence) and may have little or no difference upon the number of childhood deaths (low quality
evidence), the number of children with evidence of malaria infection in their blood (low quality evidence), or the need for children to
be admitted to hospital (low quality evidence) compared to use of clinical diagnosis.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Home- or community-based programmes for treating malaria versus facility based care
Patient or population: Children with fever or malaria symptoms
Settings: Malaria endemic areas
Intervention: Home- or community-based programmes
Control: Standard care
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Standard Care Home- or community-
based programmes
Prompt treatment with
an effective antimalarial
100 per 1000 469 per 1000
(100 to 1000)
RR 4.69
(1.00 to 22.07)
3099
(2 studies)
⊕⊕⊕©
moderate1
Both studies found
large statistically signifi-
cant benefits.
All-cause mortality 50 per 1000 29 per 1000
(22 to 39)
RR 0.58
(0.44 to 0.77)
13677
(1 study)
⊕⊕⊕©
moderate2,3
Hospitalizations 230 per 1000 145 per 1000
(81 to 269)
RR 0.63
(0.35 to 1.17)
437
(1 study)
⊕©©©
very low4,5
This single study was
conducted in an urban
setting.
Prevalence of para-
sitaemia
- - Not pooled 1443
(2 studies)
⊕©©©
very low6,7
Trials had mixed results.
Prevalence of anaemia 44 per 1000 59 per 1000
(31 to 110)
RR1.33
(0.70 to 2.51)
3612
(3 studies)
⊕⊕©©
low8,9
No statistically significant
differences were seen.
The assumed risk is the median control group risk across studies.
The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded by 1 for indirectness: All of these studies treated children with a clinical diagnosis of malaria, without parasitological
confirmation. This approach is no longer recommended by the WHO and may lead to undertreatment of other illnesses which may
require alternative treatments.
2 No serious risk of bias: Although the baseline characteristics of the intervention and control areas were not well described, deaths were
well balanced at baseline between groups.
3 Downgraded by 1 for indirectness: The study was conducted in a setting where community-based interventions such as this had been
in operation for 20 years, and so the findings may not be easily generalised to other settings.
4 Downgraded by 2 for indirectness: This study was conducted in an urban setting, which is unusual for a home-based programme. The
findings may not be applicable elsewhere.
5 Downgraded by 1 for imprecision: The trend favours the intervention but the result is not statistically significant.
6 Downgraded by 1 for inconsistency: One trial from urban Uganda demonstrated a statistically significant difference in the prevalence
of parasitaemia between the intervention and control groups, while one study from rural Burkina Faso did not.
7 Downgraded by 2 for imprecision: The data could not be pooled, and larger trials would be necessary to confidently prove or exclude a
clinically important benefit on this outcome.
8 Downgraded by 1 for risk of bias: In all three of these trials, the prevalence of anaemia was significantly reduced in both the intervention
and the control groups. The reasons for this are unclear, but include contamination or confounding.
9 Downgraded by 1 for imprecision: The confidence interval is very wide.
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B A C K G R O U N D
Malaria is an major cause of morbidity and mortality, especially
among children and pregnant women in sub-Saharan Africa.
Prompt access to diagnosis and treatment with effective antimalar-
ial drugs is a central component of theWorldHealthOrganization
(WHO) strategy for malaria control (WHO 2006; WHO 2010).
Artemisinin-based combination therapies (ACTs) are now the rec-
ommended first-line therapy for malaria (WHO 2006; Sinclair
2009). However, access to these effective treatments continues to
be a health policy challenge in many low resource settings. Re-
sults from household surveys conducted in 18 African countries
between 2006 and 2007 showed that the mean proportion of chil-
dren under five years of age with fever that were treated with an an-
timalarial drug was 38%, with only 3% of these receiving an ACT
(WHO 2008). Similarly, in 2008, data from seven African coun-
tries revealed that only 16% of children who had fever received
ACT (WHO 2009). In Kenya, about one year after the change
in treatment policy to ACT, it was found that only about 10%
of children received the recommended first line ACT (Gitonga
2008). Another study conducted in Burkina Faso found that less
than 1% of households stocked effective combination therapy for
malaria, and of those that did stock an antimalarial, 86% stocked
chloroquine (CQ) (Tipke 2009).
Access to malaria treatment can be viewed as a multidimensional
concept. The common dimensions of access include availability
(sometimes referred to as physical or spatial access), affordability
(sometimes referred to as financial access), acceptability (some-
times referred to as cultural access), accessibility, and adequacy
(Andersen 1983; McIntyre 2007; Obrist 2007).
In most countries, the cost of ACTs is significantly greater than
previously used antimalarial monotherapies, and represents a ma-
jor barrier to care.
Other barriers to accessing effective treatment for malaria include
the perceived quality of care, lack of knowledge, distance to health
services, transport costs, treatment costs, and opportunity costs
(Noor 2003; Whitty 2008). Therefore subsidies and reductions
in the price of the ACTs alone will not automatically translate to
improved access and other strategies will be needed.
Description of the intervention
Home- or community-based programmes for managing malaria
are one of the key strategies that have been proposed to over-
come the geographical barrier to access to effective malaria treat-
ment (WHO2004). TheWHOdefines home-basedmanagement
of malaria as the presumptive treatment of febrile children at or
near home with prepackaged antimalarial medicines distributed
by trained community health workers (CHWs). However, differ-
ent terminologies exist and are often used interchangeably in the
literature which can become confusing: home-based management
of malaria (HBM), home management of malaria (HMM) and
home-based management of fever (HBMF). Staedke 2009a have
argued that the term “home-basedmanagement ofmalaria” should
be used in cases with proven malaria and that “home-based man-
agement of fever” should be reserved for the presumptive treat-
ment of fevers at home without confirming a diagnosis of malaria.
In 2010, theWHOmoved frompresumptive malaria treatment to
advocate parasitological confirmationprior to treatment ofmalaria
in all patients. However this practice will not always be feasible,
and the WHO recommendations do still allow for presumptive
therapy when diagnostics are not available.
For the purpose of this review, we will explore the following home-
or community-based interventions:
1. Training mothers to presumptively treat fever with pre-
packaged antimalarials kept at home.
2. Training a basic health cadre (volunteers, CHWs, etc) to
presumptively treat fever with pre-packaged antimalarials
supplied by the state or sold in pharmacies or shops.
3. Training a basic health cadre (volunteers, CHWs, etc) to
diagnose malaria with rapid diagnostic tests (RDTs) and treat
positive results with pre-packaged antimalarials supplied by the
state or sold in pharmacies or shops.
4. Training drug sellers to use a protocol involving positive
RDT diagnosis prior to selling over the counter antimalarials.
How the intervention might work
Evidence from malaria endemic areas suggests that most episodes
of fever are treated at home with over-the-counter medication
bought from shops (McCombie 1996). In studies undertaken in
Guatemala, Ethiopia, andKenya over 60%of people self-treated at
home without seeking care from formal health facilities (Yeneneh
1993;Klein 1995; Snow 2005). InGhana,Mali,Nigeria andZam-
bia, up to 90% of children with fever were treated at home (Salako
2001), and similarly in Sudan, people often started care at home,
and then shifted to health workers if there was no improvement
(Malik 2006).
Home- or community-based programmes for the management of
malaria therefore have the potential to reduce malaria related mor-
bidity and mortality by: i) decreasing the time to treatment, and ii)
improving the quality of treatments administered at home. This
could also increase the proportion of people receiving appropriate
treatment within 24 hours of the onset of fever or malaria which
is one of the Roll Back Malaria (RBM) initiative indicators.
Conversely, in the context of the declining incidence of malaria,
the proportion of fevers caused by other illnesses (such as pneu-
monia, measles, and diarrhoea) is increasing, and presumptively
treating all fevers solely with antimalarials could adversely delay
the diagnosis and treatment of other illnesses. Accurate diagnosis
of malaria is therefore important and it has been suggested that
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RDTs to detect malaria could be incorporated into home- or com-
munity-based programmes.
Why it is important to do this review
Home- or community-based strategies for managing fever have
been adopted by many countries in Africa, but there is limited
and conflicting evidence on their effectiveness. A literature review
of home-based management strategies concluded that there was
insufficient evidence to support its widespread implementation
(Hopkins 2007). Moreover, the studies included in the review
treated all fever cases presumptively with the older antimalarial
CQ (Hopkins 2007). Following the adoption of ACTs as the first-
line antimalarial and the policy shift towards parasitological con-
firmation with RDTs, there is a need to re-examine the effective-
ness of home- and community-based strategies at improving ac-
cess to care and their impact on consequent childhood morbidity
and mortality.
O B J E C T I V E S
To evaluate home-based and community-based management
strategies for treating malaria or fever.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs) for which the unit of ran-
domization is the individual or cluster, and non-RCTs includ-
ing controlled before-and-after studies and interrupted-time-se-
ries studies.
Types of participants
People living in malaria endemic areas.
Types of interventions
Intervention
Any programme which trains mothers or caregivers, community-
based volunteers, community-based health workers, or drug sellers
to recognise and treat fevers with antimalarials presumptively or
after a positive malaria RDT.
Control
Health facility-based care; or an alternative home- or community-
based programme for recognizing and treating malaria or fevers.
Types of outcome measures
Primary outcomes
• All-cause mortality
Secondary outcomes
• Malaria-specific mortality
• Hospitalizations
• Severe malaria
• Treatment with the recommended antimalarial within 24
hours
• Treatment with any antimalarial
• Parasitaemia
• Anaemia
• Adverse events (any adverse event as reported in the
included studies)
Search methods for identification of studies
Electronic searches
We developed a highly sensitive search strategy to identify rele-
vant studies. We searched the following databases: Cochrane Cen-
tral Register of Controlled Trials (CENTRAL), published in The
Cochrane Library; MEDLINE; EMBASE; Science Citation Index;
PsycINFO/LIT; and CINAHL using the search terms detailed
in Appendix 1 up to 12 September 2012. We also searched the
WHO clinical trial registry platform and themetaRegister of Con-
trolledTrials (mRCT) for ongoing trials using the following search
terms: malaria; child*; home-based; community-based; presump-
tive treatment.
Searching other resources
We handsearched conference proceedings, including recent MIM
Pan-African Malaria Conferences (2005 and 2009).
We contacted individual researchers working in this field for un-
published and ongoing trials.
We also checked the reference lists of all studies identified by the
above methods.
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Data collection and analysis
Selection of studies
Two authors (CO and SN) independently assessed titles and ab-
stracts obtained from the searches to identify potentially eligible
studies using a study selection form.We resolved any discrepancies
through discussion. We obtained full text articles of all selected ab-
stracts to formally assess eligibility using the pre-specified eligibil-
ity criteria. We identified multiple publications of the same study
using a reference manager and we have summarized the reasons
for excluding studies in the ‘Characteristics of excluded studies’
section.
Data extraction and management
Individually randomized trials
For dichotomous outcomes in individually randomized trials, we
extracted the number of patients with the event and the total
number of patients in each group.
Cluster-RCTs
Where a trial adjusted for clustering, we extracted the adjusted
measure of effect and its 95% confidence interval (CI). However
if the trial did not adjust for clustering, we extracted the same
information as for individually randomized trials. We also aimed
to extract the method used to adjust for clustering, the unit of
randomization, the average cluster size, the number of clusters, and
the intracluster correlation co-efficient (ICC) for each outcome.
Non-randomized trials
For dichotomous outcomes in controlled before-and-after studies,
we aimed to extract event rates before and after the intervention
for the intervention and control group. If measures of effect were
presented that compared intervention versus control, we extracted
the result and noted whether the measure of effect was adjusted
for any confounders.
CO and SN independently extracted data from the studies using a
detailed data extraction form. We resolved any differences in data
extraction through discussion or, if necessary, by consulting the
third author. We extracted data on:
• Study details: citation, start and end dates, location, study
design, and study details.
• Participant details: study population eligibility (inclusion
and exclusion) criteria, ages, population size, and attrition rate.
• Details about the interventions: Nature of programme:
Who was trained? How long were they trained for? What were
they trained to do? How were they supervised? Who trained
them?
• Malaria treatment given.
• Outcome details: Outcomes including malaria related
morbidity, malaria related mortality, incidence of
hospitalizations, all-cause mortality, malaria parasitological
prevalence, and adherence to recommended dosage.
• Study site: Prevalence of malaria, available health services,
and distance to health facilities.
Assessment of risk of bias in included studies
Two authors (CO and SN) performed the assessment indepen-
dently. We resolved any differences through discussion or, if nec-
essary, by consulting the third author, AM.
Individually randomized trials
We assessed the risk of bias of all RCTs using The Cochrane Col-
laboration’s tool for assessing the risk of bias. This approach as-
sesses the risk of bias across six domains: sequence generation, al-
location concealment, blinding, incomplete outcome data, selec-
tive outcome reporting, and other potential biases (Higgins 2008).
For each domain we have assigned a judgment of ‘yes’ (low risk of
bias), ‘no’ (high risk of bias), or ‘unclear’ (unclear risk of bias).
Cluster-randomized trials
For cluster-randomized trials, we assessed recruitment bias, base-
line imbalance, loss of clusters, incorrect analysis, and compara-
bility with individual RCTs.
Non-randomized trials
For non-randomized trials, we used the Effective Practice and Or-
ganization of Care (EPOC) criteria for assessing the risk of bias (
http://epoc.cochrane.org/epoc-resources-review-authors).
Measures of treatment effect
We presented the measures of treatment effect as reported by the
trial authors, with 95% CIs and tests of statistical significance
where available.We summarized dichotomous outcomes using risk
ratios with 95% CIs (or other measures of effect if risk ratios were
not presented in the trial reports of non-randomized or cluster-
RCTs).
Unit of analysis issues
Where cluster-RCTs did not adjust for the cluster design, we con-
tacted the authors to request estimates for the ICC values so that
we could make appropriate adjustments in our analyses using the
methods described in Section 16.3.4 and 16.3.5 of the Cochrane
Handbook (Higgins 2008). None of the trial authors responded
so we sought estimates of ICC values from similar trials in malaria.
Unfortunately, we were unable to obtain any reliable estimates of
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the ICC, so we instead conducted a sensitivity analysis imputing
three different ICC values of 0.01, 0.05, and 0.1 to assess the
robustness of the results. Since all our outcomes were binary, we
divided both the numerator and denominator by the design effect
given by 1+(m-1)*ICC, where m is the average cluster size (cal-
culated by dividing the total number of participants by the total
number of clusters in both intervention and control groups), and
ICC is the intra-cluster correlation co-efficient.
As a guide to the value of this sensitivity analysis, we were able to
obtain ICCvalues from a trial of intermittent preventive treatment
of malaria in infants (Chandramohan 2005). This study was con-
ducted in rural Ghana and randomized 96 clusters of 25 children.
The estimates of ICC were 0.000 for mortality and hospital ad-
mission, 0.075 for clinical malaria, and 0.006 for severe anaemia
(Meremikwu 2008).
For one cluster RCT (Kidane 2000) which did not adjust results
for clustering but reported the mortality data for each matched
pair of clusters, we conductedmeta-analysis across the 12matched
pairs of intervention and control groups, in order to estimate the
treatment effect.
Dealing with missing data
We contacted authors where there was missing or unclear data. For
one study which only presented baseline data as a rate, without
giving specific numerators or denominators, we used the denom-
inators from the outcome data for each cluster to calculate the
number of participants and deaths in each cluster at baseline. We
did not conduct any other imputation of results.
Assessment of heterogeneity
We assessed heterogeneity amongst trials by inspecting the forest
plots (to detect overlapping CIs), the I² statistic with a level of
50% to denote moderate levels of heterogeneity, and applying the
Chi2 test with a P value of 0.10 to indicate statistical significance.
Assessment of reporting biases
We identified an insufficient number of studies to enable an as-
sessment of the likelihood of reporting bias.
Data synthesis
We analyzed the data using ReviewManager (RevMan), and com-
bined trial results in meta-analysis where appropriate. We used
the random-effects model as we are looking for an ’average’ ef-
fect rather than one true underlying effect. When a pooled meta-
analysis result was considered to be meaningless because of clinical
or substantial statistical heterogeneity, we presented the results in
a forest plot without a pooled estimate of effect. We presented
results from cluster-RCTs that did not adjust for clustering and
non-randomized studies in tables.
Quality of evidence
We assessed the quality of evidence across each outcome measure
using the GRADE approach. The quality rating across studies has
four levels: high, moderate, low, or very low. RCTs are initially
categorized as high quality but can be downgraded after assessment
of five criteria: risk of bias, consistency, directness, imprecision,
and publication bias. Similarly, observational studies are initially
categorized as low quality and can be downgraded by these same
criteria. In exceptional circumstances they may be upgraded by
three further criteria: large effect size, all plausible confounders
would act to reduce the effect size, and evidence of a dose-response
effect (Guyatt 2008).
Subgroup analysis and investigation of heterogeneity
We planned to investigate statistical heterogeneity by conduct-
ing subgroup analysis with respect to age (< 5 years of age versus
> 5 years of age), malaria endemicity, type of antimalarial used,
form of training (leaflet, presentation, one-to-one); type of train-
ing (household versus community-based); who was trained (eg
family member versus drug seller); training area (eg recognizing
fever/malaria versus treating individuals). However, we did not do
so because of the limited number of studies identified for meta-
analyses.
Sensitivity analysis
We planned to carry out a sensitivity analysis by excluding studies
with a high risk of bias from themeta-analysis, but did not do so as
there were so few trials in each comparison. However, post hoc we
decided to carry out sensitivity analysis with respect to ICC values
of 0.01, 0.05, and 0.1 in order to assess the effect of different ICC
values on the significance of the treatment effect.
R E S U L T S
Description of studies
Results of the search
The study flow diagram is shown in Figure 1. We identified 29
potentially eligible studies from 389 records. However, only 10 of
these 29 studies met the inclusion criteria for this review.
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Figure 1. Study flow diagram.
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On1May 2013 when this article was sent to press we noted several
additional studies have been published since September 2012, the
search date of this review.The editorial teambriefly appraised these
studies, and judged they are unlikely to overturn the conclusions
of this review. They are being incorporated in the review update.
Included studies
We included 10 studies conducted in different African countries
: Spencer 1987, Kenya; Delacollette 1996, Democratic Republic
of Congo (DRC); Kidane 2000, Ethiopia; Nsungwa-Sabiiti 2007,
Uganda; Kouyate 2008, Burkina Faso; Staedke 2009, Uganda;
Eriksen 2010, Tanzania; Yeboah-Antwi 2010, Zambia; Kangwana
2011, Kenya; and Mubi 2011, Tanzania)).
Six studies were parallel cluster-RCTs (Kidane 2000; Kouyate
2008; Staedke 2009; Eriksen 2010; Yeboah-Antwi 2010;
Kangwana 2011), one was a cross-over cluster-randomized trial
(Mubi 2011), and three were controlled before-and-after studies
(Spencer 1987; Delacollette 1996; Nsungwa-Sabiiti 2007).
Only four of the seven cluster-randomized studies made adjust-
ments to their results to account for the cluster design (Staedke
2009; Yeboah-Antwi 2010; Kangwana 2011; Mubi 2011), while
three did not (Kidane 2000; Kouyate 2008; Eriksen 2010). One
study was randomized by household (Staedke 2009; average clus-
ter size: one child per cluster); four were randomized by village or
clusters of villages (Kidane 2000; Kouyate 2008; Eriksen 2010;
Kangwana 2011; average cluster sizes: 217, 42, 570, and 77 re-
spectively), and two were randomized by CHW or health centre
(Yeboah-Antwi 2010; Mubi 2011; average cluster sizes: 133 and
101 respectively). In four studies, data collection was performed
through proportional surveys pre and post intervention (Kouyate
2008; Eriksen 2010; Yeboah-Antwi 2010; Kangwana 2011), and
in three studies the CHWs or mothers providing the intervention
collected the data (Kidane 2000; Staedke 2009; Mubi 2011).
All of the studies targeted children aged less than six years, except
for three studies (Spencer 1987; Delacollette 1996; Mubi 2011)
which treated all age groups.
The precise nature of the intervention varied between studies but
all 10 studies involved the training of low-level health workers or
mothers to give antimalarials. In all 10 studies the antimalarial was
provided free or at a highly subsidized cost. In eight studies the
health workers or mothers treated all episodes of fever presump-
tively with an antimalarial and this was compared to standard (fa-
cility-based) care (Spencer 1987; Delacollette 1996; Kidane 2000;
Nsungwa-Sabiiti 2007; Kouyate 2008; Staedke 2009; Eriksen
2010; Kangwana 2011). Two studies compared home- or com-
munity-based programmes using RDTs to confirm malaria with
programmes using presumptive treatment (Yeboah-Antwi 2010;
Mubi 2011). For further details see Table 1 and Table 2.
The mean duration of follow-up of the 10 studies was 12 months;
Delacollette 1996 (24months), Kouyate 2008 (15months),Mubi
2011 (5 months), Kidane 2000, Spencer 1987, Staedke 2009;
and Yeboah-Antwi 2010 (12 months each), Eriksen 2010 (9
months), Kangwana 2011 (6 months) and Nsungwa-Sabiiti 2007
(18 months).
Excluded studies
We identified 19 studies as potentially relevant. However, these
studies did not meet the review’s inclusion criteria. We have listed
the reasons for exclusion of these studies in the Characteristics of
excluded studies section.
Risk of bias in included studies
For a summary of the risk of bias assessments, see Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Six of the seven cluster-RCTsdescribed adequate random sequence
generation. However, only two studies described an adequate
method to conceal allocation and we considered them to be at
low risk for selection bias (Staedke 2009; Mubi 2011). The risk of
selection bias was unclear for the remaining five randomized trials
(Kidane 2000; Kouyate 2008; Eriksen 2010; Yeboah-Antwi 2010;
Kangwana 2011), and high for the three controlled before-and-
after studies (Spencer 1987; Delacollette 1996; Nsungwa-Sabiiti
2007).
Baseline imbalance
Only two of the cluster-RCTs provided adequate detail on baseline
characteristics to be considered at low risk of bias (Staedke 2009;
Kangwana 2011). Three studies provided only limited informa-
tion and were judged to be at unclear risk (Kidane 2000; Eriksen
2010; Mubi 2011). Two studies had evidence of important differ-
ences between groups at baseline (Kouyate 2008; Yeboah-Antwi
2010).
Of the three controlled before-and-after studies, Delacollette 1996
did not provide adequate information on the baseline characteris-
tics of the two groups, and there was evidence of important base-
line differences in both Nsungwa-Sabiiti 2007 and Spencer 1987
which could have confounded the study findings.
Contamination
Of the 10 studies, there was high risk of contamination in one
of the studies (Kouyate 2008), low risk of contamination in five
studies (Delacollette 1996; Kidane 2000;Nsungwa-Sabiiti 2007;
Yeboah-Antwi 2010; Mubi 2011) and unclear risk of contamina-
tion in four studies (Spencer 1987; Staedke 2009; Eriksen 2010;
Kangwana 2011). See Characteristics of included studies for fur-
ther details.
Blinding
Blinding of the participants in these types of studies would not
be possible. However, blinding of the study statisticians during
analysis would be possible and was not described for any of the
included studies.
Incomplete outcome data
No loss of clusters was reported in any of the cluster-RCTs,
and six studies were judged to be at low risk of attrition bias
(Kouyate 2008; Staedke 2009; Eriksen 2010; Yeboah-Antwi 2010;
Kangwana 2011;Mubi 2011).
Kidane 2000 was judged to be at high risk of bias for the outcome
’malaria specific mortality’ as only one third of all deaths had un-
dergone a verbal autopsy.
Selective reporting
We did not find evidence of selective outcome reporting.
Other potential sources of bias
Another potential source of bias was identified in Kouyate 2008,
where all the outcomes were self-reported.
Effects of interventions
See: Summary of findings for the main comparison Home- or
community-based programmes versus standard care for treating
malaria; Summary of findings 2 Home- or community-based
programmes using RDT diagnosis versus the same programmes
using clinical diagnosis
Comparison 1: Home- or community-based
interventions versus facility-based care
Treatment with the recommended antimalarial within 24
hours
Two cluster-RCTs (Kangwana 2011; Staedke 2009) reported the
proportion of fevers receiving prompt and effective treatment.
Three cluster-RCTs (Kangwana 2011; Staedke 2009; Kouyate
2008) andone controlled before-and-after study (Nsungwa-Sabiiti
2007) reported the proportion of fevers receiving any antimalarial.
In western Kenya, Kangwana 2011 trained private drug sellers and
provided them with subsidized packs of artemether-lumefantrine
(AL). After six months, the proportion of children with fever re-
ceiving AL on the same day or the following day increased from
4.7% to 44.9% in the intervention groups, and from 5.3% to
19.9% in the controls (one trial, 2662 participants, P = 0.0001,
authors own figures, see Table 3). In urban Uganda, Staedke 2009
reported that the proportion of participants with fevers receiving
chloroquine (CQ) plus sulphadoxine-pyrimethamine (SP), qui-
nine, or an artemisinin within 24 hours of the onset of fever, was
51.5% in the intervention group compared to 5.2% in the con-
trols (one trial, 437 participants, P < 0.0001, authors own fig-
ures, see Table 3). This result remained statistically significant with
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high ICC values (Analysis 1.4). All three cluster-RCTs that re-
ported the proportion of participants with fevers receiving any an-
timalarial demonstrated a larger increase in the intervention groups
than in the controls (three trials, 4105 participants, see Table 3,
Analysis 1.5). The sensitivity analysis adjusting these three trials
for the cluster-randomized design did not change the significance
of the results (Analysis 1.5). In the controlled before-and-after
study from rural Uganda (Nsungwa-Sabiiti 2007), village volun-
teers were trained to recognise fever and treat with pre-packaged
antimalarials (CQ + SP). This study coincided with a change in
national antimalarial policy from CQ to CQ + SP. The number
of fevers which were treated with the correct dosage and duration
of CQ at baseline was 7.4% in the intervention areas compared
to 7.5% in control areas. The number of fevers treated with the
correct dosage of CQ + SP post intervention was 13.5% in the
intervention areas and 0.0% in control areas presumably because
this combination was unavailable in the control areas.
All-cause mortality
Two randomized studies (Kidane 2000; Staedke 2009), and one
controlled before-and-after study (Spencer 1987), reported on
deaths occurring during follow-up.
In rural villages in Ethiopia, mothers were trained to recognise
and treat fever presumptively with CQ (Kidane 2000). The train-
ing was delivered by mother co-ordinators who had undergone
two months of training in malaria recognition and treatment, and
deaths were recorded by these same mother co-ordinators. Super-
visors from the community-based primary health care programme
(which had been operating for over 20 years), visited the mother
co-ordinators and a small sample of mothers each month. During
12 months follow-up, under-5 mortality was significantly lower
in the intervention areas than in the controls (one trial, 13,677
participants, RR 0.58, 95% CI 0.44 to 0.77, Analysis 1.1). We
performed the meta-analysis across the 12 matched pairs of inter-
vention and control groups.
In urban Uganda, mothers were trained to recognise and treat
fever presumptively with AL (Staedke 2009). The study was not
powered to assess mortality and only two deaths occurred, one in
each group (one trial, 437 participants, see Table 3).
In the controlled before-and-after study in a rural community in
western Kenya, volunteer village health workers were trained to
treat fever with CQ (Spencer 1987). The trial reported a reduction
in all-cause mortality in children under five years in the interven-
tion areas. However, the authors reported that this was likely due
to an increase in measles deaths in the intervention areas prior to
the intervention.
Malaria-specific mortality
Kidane 2000 used “verbal autopsy” to estimate the proportion
of the observed deaths which might be due to malaria in rural
Ethiopia.Deaths consistent with possiblemalaria were lower in the
intervention group but only a third of all deaths were evaluated:
13/70 (19%) in the intervention group versus 68/120 (57%) in
the controls (one trial, 13,677 participants, see Table 3).
In two controlled before-and-after studies from rural areas of DRC
and Kenya respectively, volunteers were trained to treat fevers pre-
sumptively with CQ (Spencer 1987; Delacollette 1996). Tests for
statistically significant differences between the twogroupswere not
reported in either trial. In Delacollette 1996, the malaria-specific
mortality fluctuated in both the intervention and control groups
over time, such that any effect of the intervention was impossible
to determine. In Spencer 1987, the number of deaths attributable
to malaria was low, but did not appear substantially different be-
tween groups (see Table 4).
Hospitalization
Only one RCT from urban Uganda reported on hospitalization
(Staedke 2009). The rate of hospitalization was lower among
households where mothers were trained to treat fevers with AL
but this did not reach statistical significance (one trial, 437 partic-
ipants, see Table 3).
Severe malaria
This outcome was not reported in any of the included studies.
Prevalence of parasitaemia
Two cluster-RCTs (Kouyate 2008; Staedke 2009) and two
controlled before-and-after studies (Spencer 1987; Delacollette
1996)) reported the prevalence of parasitaemia post-intervention
.
In urban Uganda, training mothers to treat fever with AL signifi-
cantly reduced the prevalence of parasitaemia compared to attend-
ing standard care (RR 0.21, 95% CI 0.07 to 0.64, one trial, 437
participants, (authors own figures adjusted) see Table 3). How-
ever, in rural Burkina Faso, a complex intervention involving the
training of mothers, mother co-ordinators, and health workers to
treat fevers with CQ found no statistically significant difference
in parasitaemia between groups (one trial, 1006 participants, see
Table 3). The sensitivity analysis adjusting these two trials for the
cluster-randomized design did not change the significance of ei-
ther of these results (Analysis 1.2).
Among the controlled before-and-after studies, Delacollette 1996
trained literate volunteers to treat fevers presumptively with CQ
and found a five-fold reduction in the prevalence of parasitaemia
compared to only a two-fold reduction in the control group (one
trial, 446 participants). Spencer 1987 found no differences in
the prevalence of parasitaemia between intervention and control
groups in both the dry and rainy seasons (one trial, 1876 partici-
pants dry season, 520 participants rainy season, see Table 5).
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Prevalence of anaemia
Three cluster -RCTs reported the prevalence of anaemia before-
and-after the intervention period (Kouyate 2008; Staedke 2009;
Eriksen 2010). The prevalence of anaemia decreased in both the
intervention and the control areas in all three trials without sta-
tistically significant differences between groups (three trials, 3612
participants, see Table 3). The sensitivity analysis using ICC val-
ues of 0.05, 0.01, and 0.1 did not change the significance of the
results (Analysis 1.3).
It is likely that this observation was due to ’contamination’ of the
control areas (people living in the control areas also benefiting
from the intervention), or confounding due to other health activi-
ties also being implemented in the study areas. Indeed, these phe-
nomena were observed and commented on by Kouyate 2008 who
noted that there were CQ and insecticide-treated bednet (ITN)
distribution activities by parallel programmes during the study pe-
riod. Staedke 2009 and Eriksen 2010 did not comment on possi-
ble reasons for this observation.
Adverse events
None of the included studies reported on adverse events.
Comparison 2: Home- or community-based
programmes using RDTs versus using clinical
algorithms
Two cluster-RCTsevaluated the introduction of RDTs for malaria
into home- or community-based programmes (Yeboah-Antwi
2010; Mubi 2011). In both studies CHWs were given one week
of refresher training in fever case management. In the intervention
areas, CHWs were trained to only treat people with fever with AL
after a positive RDT, and in control areas all fevers were treated
with AL. Mubi 2011 used a cross-over design where the initial in-
tervention and control CHWs swapped treatment arms half-way
through the study (see Table 2).
Treatment with an appropriate antimalarial
Neither Mubi 2011 nor Yeboah-Antwi 2010 reported the pro-
portion of children with fever receiving an antimalarial within
24 hours. However, in both studies compliance with the RDT
protocol was high and antimalarial use was significantly lower
in the intervention groups. In Yeboah-Antwi 2010, the propor-
tion of RDTs that were positive in the intervention arm was 271/
975 (27.8%), and subsequently 265/963 (27.5%) were given an-
timalarials compared to 2066/2084 (99.1%) in controls. In Mubi
2011, the proportion of RDTs that were positive was 733/1457
(50.3%), and subsequently 775/1457 (53.2%) were given anti-
malarials compared to 1422/1473 (96.5%) of controls. The sensi-
tivity analysis adjusting these two trials for the cluster-randomized
design did not change the significance of these results (see Analysis
2.5 and Table 6).
All-cause mortality
The studies were not powered to detect an effect on mortality. In
Yeboah-Antwi 2010, three deaths occurred: 2/1017 (0.2%) in the
intervention group versus 1/2082 (0.04%) in the control group.
Both deaths in the intervention group occurred after a negative
RDT. In Mubi 2011, four deaths occurred: 3/1457 (0.2%) in the
intervention group versus 1/1473 (0.06%) in the control group.
All four patients who died were treated with antimalarials and
referred for further care. Malaria was confirmed as the cause of
death in one patient in each group (see Table 6, Analysis 2.1).
Hospitalization
In Yeboah-Antwi 2010, hospitalization was higher in the control
group. However, this trial was not adequately powered to detect
an effect and the result did not reach statistical significance: 4/
1017 (0.4%) in the intervention group versus 14/2108 (0.7%)
in the control group (RR 0.25, 95% CI 0.04 to 1.50, one trial,
3125 participants, ; authors’ own figures adjusted for baseline fast
breathing and fever, see Table 6, Analysis 2.2).
In Mubi 2011 more patients in the intervention group were re-
ferred for further care: 104/1457 (7.1%) versus 49/1473 (3.3%)
in the control group (RR 1.89, 95% CI 1.35 to 2.65, one trial,
2930 participants, Analysis 2.3). The potential reasons for this are
not discussed by the study authors (see Table 6).
Treatment failure
Both studies reported treatment failure atDay-7. In Yeboah-Antwi
2010 there was no statistically significant difference detected in
treatment failure (one trial, 3125 participants, Analysis 2.4), but
Mubi 2011 reported thatmore than twice asmany people reported
symptoms atDay-7 in the intervention group than in controls (RR
2.15, 95% CI 1.50 to 3.09, one trial, 2869 participants; Analysis
2.4, see Table 6).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Home- or community-based programmes using RDT diagnosis versus the same programme using clinical diagnosis
Patient or population: Children with fever or malaria symptoms
Settings: Malaria endemic areas
Intervention: Home- or community-based programmes using RDT diagnosis
Control: Home- or community-based programmes using clinical diagnosis
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Clinical diagnosis RDT diagnosis
Treatment with an anti-
malarial
980 per 1000 382 per 1000
(176 to 823)
RR 0.39
(0.18, 0.84)
5977
(2 studies)
⊕⊕⊕©
moderate1
Absolute reductions in
antimalarial use in these
two trials were 72% and
43%
All-cause mortality 1 per 1,000 2 per 1,000
(0 to 11)
RR 3.51
(0.68 to 18.22)
6055
(2 studies)
⊕⊕©©
low2,3
Mortality was less than 2
per 1000 in both treat-
ment groups.
Hospitalizations 7 per 1000 2 per 1000
(0 to 11)
RR 0.25
(0.04 to 1.50)
3125
(1 study)
⊕⊕©©
low2,3
Treatment failure at day
7
- - Not pooled 5994
(2 studies)
⊕⊕©©
low1,4
Trials had mixed results.
One study showed a sta-
tistically significant in-
crease in treatment fail-
urewhenRDTswere used
while the other did not
The assumed risk is the median control group risk across studies.
The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;1
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded by 1 for serious indirectness: The introduction of RDTs was only tested in two settings. Compliance with the RDT protocol
was high under trial conditions. Further effectiveness studies may be necessary to have full confidence in this results.
2 Downgraded by 1 for serious indirectness: The introduction of RDTs was only tested in two settings. It appeared safe under trial
conditions without an increase in mortality or hospitalizations. Further effectiveness studies may be necessary to have full confidence in
this.
3 Downgraded by 1 for serious imprecision: These two studies were not powered to look for effects on mortality of hospitalization.
4 Downgraded by 1 for serious inconsistency: One of the two studies found a statistically significant increase in patients reporting
continued symptoms at day 7. The reasons for this are unclear.
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D I S C U S S I O N
Summary of main results
We identified 10 trials that met the inclusion criteria. The inter-
ventions involved brief training of basic-level health workers or
mothers, and most provided the antimalarial for free or at a highly
subsidized cost. In eight of the studies, fevers were treated pre-
sumptively without parasitological confirmation with microscopy
or a rapid diagnostic test (RDT). Two studies trained community
health workers to use RDTs as a component of community man-
agement of fever.
Home- or community-based strategies probably increase the num-
ber of people with fever who receive an appropriate antimalarial
within 24 hours (moderate quality evidence). They may also reduce
all-cause mortality, but to date this has only been demonstrated in
rural Ethiopia (moderate quality evidence).
Hospital admissions in children were reported in one small trial
from urban Uganda, with no effect detected (very low quality ev-
idence). No studies reported on severe malaria. For parasitaemia
prevalence, the study from urban Uganda demonstrated a reduc-
tion in community parasite prevalence, but a second study in rural
Burkina Faso did not. Home- or community-based programmes
may have little or no effect on the prevalence of anaemia (low
quality evidence). None of the included studies reported on ad-
verse effects of using home- or community-based programmes for
treating malaria.
In two studies which trained community health workers to only
prescribe antimalarials after a positive RDT, prescriptions of an-
timalarials were reduced compared to the control group where
community health workers used clinical diagnosis (moderate qual-
ity evidence). In these two studies, mortality and hospitalizations
remained very low in both groups despite the lower use of anti-
malarials (low quality evidence).
Overall completeness and applicability of
evidence
The home- or community-based programmes evaluated in the
10 included studies were all complex interventions combining
several different elements, and often addressed more than one
of the common barriers to accessing care. For example, home-
and community-based programmes were often discussed in the
context of reducing the geographical barrier to care (the distance
to the health facility), but the financial barrier was also reduced (by
providing the antimalarial free or at a highly subsidized cost), and
all studies addressed the educational barriers (through community
awareness, social marketing, training of mothers or CHWs).
We are unable to determine which of these barriers was most
important locally, or which of the elements were most responsible
for the observed effects. Therefore, only broad conclusions can be
drawn from these data, and local knowledge of the barriers to access
will be of equal importance when designing and implementing
new programmes.
Eight of the studies relied on the presumptive treatment of fevers
without confirmationofmalaria, and this strategywould undoubt-
edly result in significant overuse of antimalarials in most settings.
To reduce this overtreatment and to refocus health providers on
the alternative causes of fever, theWHOnow recommends that all
episodes of malaria are confirmed parasitologically prior to treat-
ment (WHO 2010).
For basic health workers, RDTs are the most feasible option to
achieve this. Yeboah-Antwi 2010 and Mubi 2011 demonstrated
that this can be done safely under trial conditions, but further
monitoring of adherence to RDT protocols and safety under real-
life conditions is warranted. These studies demonstrated a signifi-
cant reduction in use of antimalarials, but one study also demon-
strated an increase in subsequent referrals to high levels of care.
This increase is a potential benefit of programmes using RDTs if
these children, who tested negative for malaria, now receive earlier
management of their alternative diagnosis.
Nine of the 10 studies were conducted in rural areas of sub-
Saharan Africa countries where these programmes are currently
promoted. However, Staedke 2009 demonstrated that these pro-
grammes could also be considered in urban settings where malaria
is common and access to antimalarials is low.
Quality of the evidence
We assessed the quality of evidence provided by the randomized
studies using the GRADE approach. We have presented these
results in Summary of findings for the main comparison and
Summary of findings 2. The results of the non-randomized stud-
ies were included as footnotes where appropriate. In general, the
results of the non-randomized studies were inconsistent, and did
not contribute significantly to the overall body of evidence.
We judged the evidence that home- or community-based strategies
can increase access to, and use of, antimalarials to be of moderate
quality, with consistent increases across all three trials. Also, we
found the quality of evidence for the primary outcome (all-cause
mortality) to be moderate, which implies that we can have reason-
able confidence in the result but further research may change the
estimate of effect. The evidence from this single trial was down-
graded due to concerns about generalizing this result to other set-
tings. The reduction in mortality observed in this trial appeared
large and important, but as the barriers to accessing care formalaria
are likely to differ across settings, further studies from different
settings are necessary to have full confidence that this result could
be widely applied.
Potential biases in the review process
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None were identified.
Agreements and disagreements with other
studies or reviews
Three of the studies included in this review (Spencer 1987;
Delacollette 1996; Kidane 2000) were also included in a review of
home-based management of malaria published in 2007 (Hopkins
2007). The authors of this review concluded that “Presumptive
treatment of febrile children with pre-packaged antimalarials in
Home-based Management of Malaria programmes is likely to in-
crease delivery of effective drugs, and improve the timing, adher-
ence, and dosing of treatment. Results from evaluations of com-
munity acceptability and feasibility are encouraging, but further
study of health outcomes, including the impact on morbidity and
mortality, will provide stronger evidence to support sustained im-
plementation of community-based interventions”.
In this review, we excluded some of the observational studies in-
cluded by Hopkins 2007, but we added several cluster-RCTs that
been published since the Hopkins 2007 review (Kouyate 2008;
Staedke 2009, Yeboah-Antwi 2010;Kangwana 2011;Mubi 2011).
We also concluded that these interventions are likely to improve
access to antimalarials, especially in rural or remote areas.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Home- or community-based interventions which provide anti-
malarial drugs free of charge probably improve prompt access
to antimalarials. There is moderate quality evidence from rural
Ethiopia that they may impact on childhood mortality when im-
plemented in appropriate settings.
Programmes which treat all fevers presumptively with antimalar-
ials are likely to overuse antimalarial drugs, and potentially un-
dertreat other causes of fever such as pneumonia. Incorporating
RDT diagnosis into home- or community-based programmes for
malaria may help to reduce this overuse of antimalarials, and has
been shown to be safe under trial conditions.
Implications for research
Further well designed trials evaluating programmes which include
parasitological confirmation with RDTs are needed to further
guide practice.
The studies should report on adverse events, severe malaria and
malaria-specific mortality.
A C K N OW L E D G E M E N T S
This project was funded by a grant from the Alliance for Health
Policy and Systems Research (HSS/AHPSR), WHO, Geneva.
Matin Meremikwu is the Academic Editor of this review. The ed-
itorial base for the Cochrane Infectious Diseases Group is funded
by the UK Department for International Development (DFID)
for the benefit of low- and middle-income countries.
R E F E R E N C E S
References to studies included in this review
Delacollette 1996 {published data only}
Delacollette C, Van der Stuyft P, Molima K. Using
community health workers for malaria control: experience
in Zaire. Bulletin of the World Health Organization 1996;74
(4):423–30.
Eriksen 2010 {published data only}
Eriksen J, Mujinja P, Warsame M, Nsimba S, Kouyate
B, Gustafsson LL, et al.Effectiveness of a community
intervention on malaria in rural Tanzania - a randomised
controlled trial. African Health Sciences 2010;10(4):332–40.
Kangwana 2011 {published data only}
Kangwana BP, Kedenge SV, Noor AM, Alegana VA,
Nyandigisi AJ, Pandit J, et al.The impact of retail-sector
delivery of artemether-lumefantrine on malaria treatment
of children under five in Kenya: a cluster randomized
controlled trial. PLoSMedicine 2011;8(5):e1000437.
Kidane 2000 {published data only}
Kidane G, Morrow RH. Teaching mothers to provide home
treatment of malaria in Tigray, Ethiopia: a randomised trial.
Lancet 2000;356(9229):550–5.
Kouyate 2008 {published data only}
Kouyaté B, Somé F, Jahn A, Coulibaly B, Eriksen J,
Sauerborn R, et al.Process and effects of a community
intervention on malaria in rural Burkina Faso: randomized
controlled trial. Malaria Journal 2008;7(50):1–13.
Mubi 2011 {published data only}
Mubi M, Janson A, Warsame M, Mårtensson A, Källander
K, Petzold MG, et al.Malaria rapid testing by community
health workers Is effective and safe for targeting malaria
treatment: randomised cross-over trial in Tanzania. PLoS
ONE 2011;6(7):e19753.
Nsungwa-Sabiiti 2007 {published data only}
Nsungwa-Sabiiti J, Peterson S, Pariyo G, Ogwal-Okeng J,
Petzold MG, Tomson G. Home-based management of fever
18Home- or community-based programmes for treating malaria (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
and malaria treatment practices in Uganda. Transactions of
the Royal Society of Tropical Medicine and Hygiene 2007;101
(12):1199–207.
Spencer 1987 {published data only}
Spencer HC, Kaseje DC, Collins WE, Shehata MG,
Turner A, Stanfill PS, et al.Community-based malaria
control in Saradidi, Kenya: description of the programme
and impact on parasitaemia rates and antimalarial
antibodies. Annals of Tropical Medicine and Parasitology
April 1987;81(Suppl 1):13–23.
Staedke 2009 {published data only}
Staedke SG, Mwebaza N, Kamya MR, Clark TD, Dorsey
G, Rosenthal PJ, et al.Home management of malaria with
artemether-lumefantrine compared with standard care in
urban Ugandan children: a randomised controlled trial.
Lancet 2009;373(9675):1623–31.
Yeboah-Antwi 2010 {published data only}
Yeboah-Antwi K, Pilingana P, Macleod WB, Semrau K,
Siazeele K, Kalesha P, et al. Community case management
of fever Due to malaria and pneumonia in children under
five in Zambia: a cluster randomized controlled trial. PLoS
Medicine 2010;7(9):e1000340.
References to studies excluded from this review
Abuya 2010 {published data only}
Abuya TO, Fegan G, Amin AA, Akhwale WS, Noor
AM, Snow RW, et al. Evaluating different dimensions
of programme effectiveness for private medicine retailer
malaria control interventions in Kenya. PLoS One 2010;5
(1):e8937.
Ahorlu 2009 {published data only}
Ahorlu CK, Koram KA, Seakey AK, Weiss MG.
Effectiveness of combined intermittent preventive treatment
for children and timely home treatment for malaria control.
Malaria Journal 2009;8(292):1–7.
Ajayi 2008a {published data only}
Ajayi IO, Falade CO, Bamgboye EA, Oduola AM, Kale
OO. Assessment of a treatment guideline to improve home
management of malaria in children in rural south-west
Nigeria. Malaria Journal 2008;7(24):1–12.
Ajayi 2008b {published data only}
Ajayi IO, Falade CO, Kale OO. An assessment of accuracy
of mothers’ presumptive diagnosis of fever at home in
southwest Nigeria: evidence for switch to parasite-based
diagnostic test. East African Journal of Public Health 2009;6
(3):229–34.
Ajayi 2008c {published data only}
Ajayi IO, Browne EN, Garshong B, Bateganya F, Yusuf
B, Agyei-Baffour P, et al.Feasibility and acceptability of
artemisinin-based combination therapy for the home
management of malaria in four African sites. Malaria
Journal 2008;7(6):1–9.
Ansah 2010 {published data only}
Ansah EK, Narh-Bana S, Epokor M, Akanpigbiam S,
Quartey AA, Gyapong J, et al.Rapid testing for malaria
in settings where microscopy is available and peripheral
clinics where only presumptive treatment is available: a
randomised controlled trial in Ghana. BMJ 2010;340
(c930):1–9.
Bojang 2009 {published data only}
Bojang KA, Sesay S, Sowe M, Conway D, Milligan P,
Greenwood B. A study of intermittent preventive treatment
and home based management of malaria in a rural area of
The Gambia. American Journal of Tropical Medicine and
Hygiene. 2009.
Chinbuah 2006 {published data only}
Chinbuah AM, Gyapong JO, Pagnoni F, Wellington EK,
Gyapong M. Feasibility and acceptability of the use of
artemether-lumefantrine in the home management of
uncomplicated malaria in children 6-59 months old in
Ghana. Tropical Medicine and International Health 2006;11
(7):1003–16.
Dunyo 2000 {published data only}
Dunyo SK, Afari EA, Koram KA, Ahorlu CK, Abubakar
I, Nkrumah FK. Health centre versus home presumptive
diagnosis of malaria in southern Ghana: implications for
home-based care policy. Transactions of the Royal Society of
Tropical Medicine and Hygiene 2000;94(3):285–8.
Elmardi 2008 {published data only}
Elmardi KA, Malik EM, Abdelgadir T, Ali SH, Elsyed AH,
Mudather MA, et al.Feasibility and acceptability of home-
based management of malaria strategy adapted to Sudan’s
conditions using artemisinin-based combination therapy
and rapid diagnostic test. Malaria Journal 2009;8(39):1–8.
Greenwood 1988 {published data only}
Greenwood BM, Greenwood AM, Bradley AK, Snow RW,
Byass P, Hayes RJ, et al. Comparison of two strategies for
control of malaria within a primary health care programme
in the Gambia. Lancet 1988;1(8595):1121–7.
Moir 1985 {published data only}
Moir JS, Tulloch JL, Vrbova H, Jolley DJ, Heywood PF,
Alpers MP. The role of voluntary village aides in the control
of malaria by presumptive treatment of fever. 2. Impact
on village health. Papua and New Guinea Medical Journal
1985;28(4):267–278.
Ngasala 2011 {published data only}
Ngasala BE, Malmberg M, Carlsson AM, Ferreira PE,
Petzold MG, Blessborn D, et al.Effectiveness of artemether-
lumefantrine provided by community health workers in
under-five children with uncomplicated malaria in rural
Tanzania: an open label prospective study. Malaria Journal
2011;10(64):1–10.
Pagnoni 1997 {published data only}
Pagnoni F, Convelbo N, Tiendrebeogo J, Cousens S,
Esposito F. A community-based programme to provide
prompt and adequate treatment of presumptive malaria
in children. Transactions of the Royal Society of Tropical
Medicine and Hygiene 1997;91(5):512–7.
Pence 2005 {published data only}
Pence BW, Nyarko P, Phillips JF, Debpuur C. The effect of
community nurses and health volunteers on child mortality:
19Home- or community-based programmes for treating malaria (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
the Navrongo Community Health and Family Planning
Project. Scandinavian Journal of Public Health 2005;35(6):
599–608.
Sesay 2011 {published data only}
Sesay S, Milligan P, Touray E, Sowe M, Webb EL,
Greenwood BM, et al.A trial of intermittent preventive
treatment and home-based management of malaria in a
rural area of The Gambia. Malaria Journal 2011;10(2):1–9.
Sirima 2003 {published data only}
Sirima SB, Konaté A, Tiono AB, Convelbo N, Cousens
S, Pagnoni F. Early treatment of childhood fevers with pre-
packaged antimalarial drugs in the home reduces severe
malaria morbidity in Burkina Faso. Tropical Medicine and
International Health 2003;8(2):133–9.
Skarbinski 2009 {published data only}
Skarbinski J, Ouma PO, Causer LM, Kariuki SK,
Barnwell JW, Alaii JA, et al.Effect of malaria rapid
diagnostic tests on the management of uncomplicated
malaria with artemether-lumefantrine in Kenya: a cluster
randomized trial. The American Journal of Tropical Medicine
and Hygiene 2009;80(6):919–26.
Tiono 2008 {published data only}
Tiono AB, Kaboré Y, Traoré A, Convelbo N, Pagnoni F,
Sirima SB. Implementation of home based management of
malaria in children reduces the work load for peripheral
health facilities in a rural district of Burkina Faso. Malaria
Journal 2008;7(201):1–8.
References to ongoing studies
Ohnmar 2010 {unpublished data only}
Ohnmar. Cluster randomized trial on the use of community
volunteers to improve early diagnosis and appropriate
treatment of malaria in Bago Division, Myanmar. Australian
New Zealand Clinical Trials Registry Accessed 25 September
2012:ACTRN12610000706077.
Additional references
Andersen 1983
Andersen RM, McCutcheon A, Aday LA, Chiu GY, Bell
R. Exploring dimensions of access to medical care. Health
Services Research 1983;18(1):49–74.
Chandramohan 2005
Chandramohan D, Owusu-Agyei S, Carneiro I, Awine T,
Amponsa-Achiano K, Mensah M, et al.Cluster randomised
trial of intermittent preventive treatment for malaria in
infants in area of high, seasonal transmission in Ghana.
BMJ 2005;331(7519):727–33.
Gitonga 2008
Gitonga CW, Amin AA, Ajanga A, Kangwana BB, Noor
AM, Snow RW. The use of artemether-lumefantrine by
febrile children following national implementation of
a revised drug policy in Kenya. Tropical Medicine and
International Health 2008;13(4):487–94.
Guyatt 2008
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek
J, et al.GRADE guidelines: 1. Introduction-GRADE
evidence profiles and summary of findings tables. Journal of
Clinical Epidemiology 2011;64(4):383–94.
Higgins 2008
Higgins JPT, Green S (editors). Cochrane Handbook for
Systematic Reviews of Interventions. Chichester: John Wiley
& Sons, Ltd., 2008.
Hopkins 2007
Hopkins H, Talisuna A, Whitty CJ, Staedke SG. Impact
of home-based management of malaria on health outcomes
in Africa: a systematic review of the evidence. Malaria
Journal 2007;6(134):1–10.
Klein 1995
Klein RE, Weller SC, Zeissig R, Richards FO, Ruebush
TK 2nd. Knowledge, beliefs, and practices in relation to
malaria transmission and vector control in Guatemala.
American Journal of Tropical Medicine and Hygiene 1995;52
(5):383–8.
Malik 2006
Malik EM, Hanafi K, Ali SH, Ahmed ES, Mohamed KA.
Treatment-seeking behaviour for malaria in children under
five years of age: implication for home management in rural
areas with high seasonal transmission in Sudan. Malaria
Journal 2006;5(60):1–5.
McCombie 1996
McCombie SC. Treatment seeking for malaria: a review
of recent research. Social Science & Medicine 1996;43(6):
933–45.
McIntyre 2007
McIntyre D, Mooney G (editors). The economics of health
equity. Cambridge, UK: Cambridge University Press, 2007.
Meremikwu 2008
Meremikwu MM, Donegan S, Esu E. Chemoprophylaxis
and intermittent treatment for preventing malaria in
children. Cochrane Database of Systematic Reviews 2008,
Issue 2. [DOI: 10.1002/14651858.CD003756.pub3]
Noor 2003
Noor AM, Zurovac D, Hay SI, Ochola SA, Snow
RW. Defining equity in physical access to clinical services
using geographical information systems as part of malaria
planning and monitoring in Kenya. Tropical Medicine &
International Health 2003;8(10):917–26.
Obrist 2007
Obrist B, Iteba N, Lengeler C, Makemba A, Mshana
C, Nathan R, et al. Access to health care in contexts of
livelihood insecurity: a framework for analysis and action.
PLoS Medicine 2007; Vol. 4, issue 10:1584–8.
Review Manager (RevMan)
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). 5.2. Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2012.
20Home- or community-based programmes for treating malaria (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Salako 2001
Salako LA, Brieger WR, Afolabi BM, Umeh RE, Agomo
PU, Asa S, et al.Treatment of childhood fevers and other
illnesses in three rural Nigerian communities. Journal of
Tropical Pediatrics 2001;47(4):230–8.
Sinclair 2009
Sinclair D, Zani B, Donegan S, Olliaro P, Garner P.
Artemisinin-based combination therapy for treating
uncomplicated malaria. Cochrane Database of
Systematic Reviews 2009, Issue 3. [DOI: 10.1002/
14651858.CD007483.pub2]
Snow 2005
Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI.
The global distribution of clinical episodes of Plasmodium
falciparum malaria. Nature 2005;434(7030):214–7.
Staedke 2009a
Staedke SG, Mwebaza N, Kamya MR, Rosenthal PJ,
Whitty CJM. Home management of malaria - Authors’
reply. Lancet 2009;374(9686):289.
Tipke 2009
Tipke M, Louis VR, Yé M, De Allegri M, Beiersmann C,
Sié A, et al. Access to malaria treatment in young children
of rural Burkina Faso. Malaria Journal 2009;8(266):1–10.
Whitty 2008
Whitty CJM, Chandler C, Ansah E, Leslie T, Staedke
SG. Deployment of ACT antimalarials for treatment of
malaria: challenges and opportunities. Malaria Journal
2008;7(Suppl 1):1–7.
WHO 2004
World Health Organization. Scaling up home-
based management of malaria: from research to
implementation. http://apps.who.int/tdr/svc/publications/
training-guideline-publications/scaling-up-home-based-
management 2004 (accessed 12 April 2011).
WHO 2006
World Health Organization. WHO briefing on malaria
treatment guidelines and artemisinin monotherapies.
http://www.who.int/malaria/publications/atoz/
meeting˙briefing19april/en/index.html 2006 (accessed 12
April 2011).
WHO 2008
World Health Organization. World Malaria Report
2008. http://www.who.int/malaria/publications/atoz/
9789241563697/en/index.html (accessed 12 April 2011).
WHO 2009
World Health Organization. World Malaria Report 2009.
http://www.who.int/malaria/world˙malaria˙report˙2009/
en/index.html (accessed 12 April 2011).
WHO 2010
World Health Organization. Guidelines for the treatment
of malaria. http://www.who.int/malaria/publications/atoz/
9789241547925/en/index.html (accessed 12 April 2011).
Yeneneh 1993
Yeneneh H, Gyorkos TW, Joseph L, Pickering J, Tedla
S. Antimalarial drug utilization by women in Ethiopia: a
knowledge-attitudes-practice study. Bulletin of the World
Health Organization 1993;71(6):763–72.
∗ Indicates the major publication for the study
21Home- or community-based programmes for treating malaria (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Delacollette 1996
Methods Trial design: Controlled before-and-after study
Study areas: ‘Area A’ Intervention: 12 villages, ‘Area B’ Control: Not described
Data Collection: Four household surveys at six monthly intervals
Length of follow-up: 24 months
Participants Target treatment group: All ages
Sample size: Population of Area A approximately 13,000
Exclusions: None stated
Interventions The intervention:
• Who was trained? One ‘literate volunteer’ for each village
• How long they were trained for? Two weeks
• What they were trained to do? Treat fever with CQ for three days. Keep records of
patients treated.
• How they were supervised? Close supervision by nurses from the health centre.
• Were the antimalarials given free? No, but ’three times cheaper than at the health
centre’
• Additional details: The volunteers received ’only a symbolic monetary reward’
The control group: Facility-based care only
Outcomes Outcomes included in the review:
• Malaria mortality
• Malarial illness incidence and prevalence
• Parasitological index
Outcomes not included in this review:
• Proportion of fevers being treated at home
• Source of treatment
Notes Country: Zaire, DRC
Setting: Rural, Kotana health zone
Malaria endemicity: Meso-endemic, continuous transmission with seasonal fluctuations
Study dates: 1985 to 1987
Study sponsor: UNDP/World Bank/WHO Special Programme for Research and Train-
ing in Tropical Diseases, and the Belgian Administration for Development Co-operation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Controlled before-and-after study (no ran-
domization)
Allocation concealment (selection bias) High risk Not applicable
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Delacollette 1996 (Continued)
Baseline imbalance Unclear risk Few details. ’The areas had the same malar-
ial ecology, and malariometric indices’
Contamination Low risk Contamination is unlikely due to the dis-
tance between the study intervention and
control sites
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data collection was through pre and post-
intervention cross-sectional surveys. Each
survey sampled between 200 to 300 partic-
ipants from populations of around 14,000
Loss of clusters Low risk Not applicable
Selective reporting (reporting bias) Low risk No evidence of selective reportingwas iden-
tified
Other bias Low risk Noother potential sources of bias identified
Eriksen 2010
Methods Trial design: Cluster RCT
Unit of randomization: Villages
Number of clusters: 10 villages in total, five in intervention, five in control
Data collection: Pre and post intervention survey
Length of follow-up: Nine months
Authors did not adjust for clustering
Participants Target treatment group: Children under the age of five
Sample size: 1715 pre-intervention survey and 2169 post-intervention
Exclusions: None described
Interventions The intervention group:
• Who was trained? Two groups: health workers and women leaders.
• How long they were trained for? Seven days (both groups).
• What they were they trained to do? Health workers were trained in the principles
of malaria case management. Women leaders were trained to identify fever, treat with a
single dose of SP and refer severe cases or other diseases.
• How they were supervised? Two health workers conducted the training of the
women leaders and visited them every two weeks using standardized check lists. The
research team also conducted four weekly supervision meetings with the women leaders
and health workers.
• Were antimalarials given free? Yes.
• Additional details: The women leaders were paid 20 USD per month. Several
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Eriksen 2010 (Continued)
community meetings were held to publicise the intervention.
The control group: Usual practice - no details provided.
Outcomes Included in this review:
• Prevalence of moderate and severe anaemia (haemoglobin < 8 g/dL and < 5 g/dL
respectively by colour scale)
Outcomes not included in this review:
• Prevalence of measured fever (Axillary temp > 37.5°C)
• Reported fever during the last 48 hours
• Mean malaria parasite densities
• Mean haemoglobin values
• Mean weight
Notes Country: Tanzania, Mkuranga District, Coast region of Tanzania
Setting: Unclear
Malaria endemicity: Holoendemic, peak transmission in January and June
Study dates: April 2004 to May 2005
Study sponsors: EU INCO-DEV funded collaboration between the Karolinska Institute
(Sweden), Heidelberg University (Germany), Muhimbili University College of Health
Sciences (Tanzania) and Centre de Recherce en Sante de Nouna (Burkina Faso) called
the MAMOP project
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “From the remaining 20 wards, 10 were
randomly selected for theMAMOPproject
in a computer randomization (Excel)’. ’The
intervention was implemented in 5 ran-
domly chosen wards”
Allocation concealment (selection bias) Unclear risk Allocation concealment was not described.
Baseline imbalance Unclear risk Some baseline imbalance in education
level’s of mothers but statistical significance
not reported
Contamination Unclear risk The potential for contamination is not
discussed by the study authors. However,
the prevalence of anaemia substantially
reduced in both treatment and control
groups during the study period. The rea-
sons for this are unclear but include con-
tamination or confounding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk ’There was no blinding in the study design’.
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Eriksen 2010 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Data collection was through pre-and post
intervention surveys.One village from each
ward was randomly selected for the survey.
It is unclear what proportion of the total
study population this represents
Loss of clusters Low risk No loss of clusters reported.
Selective reporting (reporting bias) Low risk No evidence of selective reportingwas iden-
tified.
Other bias Low risk No other bias identified.
Kangwana 2011
Methods Trial Design: Cluster RCT
Unit of randomization: Sublocations (population 2,500 to 10,000)
Number of clusters: 18, nine intervention and nine control sublocations
Data collection: Pre and post-intervention household surveys
Length of follow-up: Six months
The authors adjusted for clustering
Participants Target treatment group: Children aged three to 59 months
Sample size: Estimated population: control 38,620 versus 44,538 intervention
Exclusions: Urban and peri-urban sublocations (due to risk of contamination)
Interventions The intervention:
• Who was trained? Retail outlet staff (shopkeepers).
• How long they were trained for? One day.
• What they were they trained to do? Clinically diagnose and treat malaria with AL,
recognise adverse drug reactions and refer patients.
• How they were supervised? Shopkeepers kept records of dispensing and referrals
which were collected by the study staff. A follow-up three month supervisory visit was
made by the implementation team.
• Were antimalarials given free? No, but they were highly subsidized.
• Additional details: Trained outlets were supplied with job aids, consisting of a
referral flow chart and dosing guidelines. Community malaria awareness events and
extensive social marketing of branded AL were conducted.
Control group: There was no intervention, but AL was available free at all government
facilities
Outcomes Outcomes included in the review:
• The proportion of children reporting fever in the past two weeks who started
treatment with AL on the same day or following day of fever onset
• The proportion of children with fever who received any antimalarial
Outcomes not included in the review:
• Adequacy of AL doses obtained and consumed
• Price paid per pack
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Kangwana 2011 (Continued)
Notes Country: Kenya
Setting: Three rural districts in Kenya’s western province.
Malaria endemicity: HIgh
Study dates: August 2009 to May 2010
Study sponsors: KEMRI
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated random numbers
(Excel). Described as a ’modified random-
ization process’ where if intervention and
control sublocations were deemed to be too
close and at risk of contamination, the list
was reshuffled and the sublocation rese-
lected
Allocation concealment (selection bias) Unclear risk None described.
Baseline imbalance Low risk The authors have presented the baseline
characteristics for both in the intervention
and control group at baseline and follow-
up. Although there are no direct statistical
tests performed there appears to be low risk
of imbalance of baseline characteristics
Contamination Unclear risk ’In order to reduce the potential for con-
tamination, a buffer zone was created
around selected sublocations’
Despite the buffer zones, the proportion of
children receiving antimalarials, and receiv-
ing AL increased substantially in the con-
trol groups. The authors comment that this
may be due to reduced stock-outs in the
government facilities
Blinding of outcome assessment (detection
bias)
All outcomes
High risk There was no blinding.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data collection was through pre-and post
intervention surveys. It is unclear what pro-
portion of the total study population this
represents
Loss of clusters Low risk No loss of clusters reported.
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Kangwana 2011 (Continued)
Selective reporting (reporting bias) Low risk The authors have presented all outcomes
which they intended to report and also pro-
vided further data
Other bias Low risk No other forms of bias identified.
Kidane 2000
Methods Trial design: Cluster RCT
Unit of randomization: ‘tabias’ - a cluster of villages
Number of clusters: 24 tabias, 12 intervention and 12 control
Data collection: The mother co-ordinators kept records of births, deaths and migration.
Malaria specific mortality was ascertained by verbal autopsy
Length of follow-up: 12 months
The authors did not adjust for clustering
Participants Target treatment group: Children under five
Sample size: 13,677 children, control: 7924, intervention: 6383
Exclusions: None stated
Interventions The intervention:
• Who was trained? Mother coordinators and mothers.
• How long they were trained for? Mother coordinators trained for two months.
• What they were trained to do? Mother coordinators taught to keep record of
births, deaths and taught to refer sick children. In turn they taught mothers
recognition and treatment of malaria with CQ.
• How they were supervised? Seven field supervisors were appointed to supervise
the tabia co-ordinators through four to six visits per month and directly supervise a
sample of mothers by visiting at least five of them per day.
• Were the antimalarials given free? Yes.
• Additional details: Age-dose charts given to coordinators. C
Control group: Facility-based approach, mother coordinators were simply taught to
record births, deaths and migration
Outcomes Outcomes included in this review:
• Under five years of age all-cause mortality
• Malaria specific mortality
Outcomes not included in this review: None
Notes Country: Ethiopia
Setting: Rural villages in an area where a community-based primary health care pro-
gramme had been operating the health system for over 20 years and the CHWs dis-
tributing the drugs had been frequently supervised
Malaria endemicity: Seasonal hyperendemic
Study dates: November 1996 to December 1997
Study sponsors: The UNDP/World Bank/WHO Special Programme for Research and
Training in Tropical Diseases
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Kidane 2000 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Tabias were paired according to similar
mortality rates. One tabia of each of the
12 pairs was allocated by random number
to the intervention group and the other to
control. It was not clear how this was gen-
erated, however it is likely to be at low risk
Allocation concealment (selection bias) Unclear risk None described.
Baseline imbalance Unclear risk The baseline under-five mortality rates of
the 24 tabias varied from 8.4 per 1000 to
158.3 per 1000. The average baseline mor-
tality in the control tabias was 47.6 per
1000, compared to 60.8 per 1000 in the
intervention tabias, and this difference is
not statistically significant. Other baseline
characteristics were not presented
Contamination Low risk No evidence of contamination was identi-
fied, and contamination would be likely to
lead to an underestimation of any effect
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding of children, parents and health
workers was not be possible. As health
workers collected the data some reporting
bias is possible. No blinding is described at
the analysis stage
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details provided on potential attrition.
Loss of clusters Low risk No loss of clusters reported.
Selective reporting (reporting bias) Low risk No evidence of selective outcome reporting
was identified.
Other bias Low risk Although only few verbal autopsies were
performed this was assessed by two investi-
gators and the second assessor was masked
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Kouyate 2008
Methods Trial design: Cluster RCT
Unit of randomization: Villages
Number of clusters: 13 villages, six intervention and seven control
Data collection: Pre and post-intervention household surveys
Length of follow-up: 15 months
The authors did not adjust for clustering.
Participants Target treatment group: Children aged six to 59 months
Sample size: 1083 children at baseline, 1006 at follow-up
Exclusions: None stated
Interventions The intervention:
• Who was trained? Three groups: health workers (nurses), women group leaders
and caretakers (usually mothers) of preschool children.
• How long they were trained for? Health workers were trained for five days by the
study investigators and the district medical officer. Group leaders were trained for two
days by the health workers. Mothers were trained for half a day.
• What they were trained to do? Health workers were given an update in malaria
case management and in turn trained group leaders in malaria knowledge and
management with CQ including referral criteria. Group leaders in turn trained an
average of 15 mothers in their sub-villages on the correct management of malaria.
• How they were supervised? Health workers visited the sub-villages monthly. The
trial investigators carried out overall supervision - monthly visits for the first three
months, and thereafter every three months.
• Were antimalarials given free? No, the group leaders were allowed to sell them on
for a small fee.
• Additional details: Group leaders were supplied with a free six month supply of
pre packed CQ and paracetamol doses.
The control group: Village based health centres, no intervention
Outcomes Outcomes included in this review:
• Fever episodes treated with CQ
• Prevalence of parasitaemia
• Prevalence of anaemia
Outcomes not included in the review:
• Self reported fever in last two days
• Place of treatment (home or health centre)
• Involvement of women group leaders in CQ treatment at follow-up
• Prevalence of fever ≥ 37.5°C)
• Prevalence of malaria (fever +≥ 5000 parasitaemia/µl)
• Prevalence of palpable spleen (Hackett score ≥ 2)
• CQ efficacy
Notes Country: Burkina Faso
Setting: Rural
Malaria endemicity: Holoendemic but highly seasonal
Study dates: July 2003 to October 2004
Study sponsor: EU INCO-DEV
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Kouyate 2008 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Villages were selected by lottery until an ap-
proximate sample size of 1200 households
per study arm was achieved. Assignment of
clusters not clear
Allocation concealment (selection bias) High risk None described.
Baseline imbalance High risk The baseline use of CQ was higher in the
control compared to the intervention vil-
lages which shows that the that interven-
tion and control area differed with regard
to treatment behaviour
Contamination High risk The prevalence of anaemia substantially
reduced in both treatment and control
groups during the study period. The au-
thors note that there were CQ and ITN
distribution activities in the control areas
by parallel programmes during the study
period
Blinding of outcome assessment (detection
bias)
All outcomes
High risk There was no blinding and all data is self
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data collection was through pre-and post
intervention surveys. It is unclear what pro-
portion of the total study population this
represents
Loss of clusters Low risk No loss of clusters reported.
Selective reporting (reporting bias) Low risk No evidence of selective outcome reporting
was identified.
Other bias High risk No other forms of bias identified.
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Mubi 2011
Methods Trial design: cross-over cluster RCT
Unit of randomization: CHWs
Number of clusters: 22
Data collection: CHWs collected data on new patients and at day 3 and 7
Length of follow-up:Five months
The authors adjusted data for clustering at the CHW level
Participants Target treatment group: people aged three months and older
Sample size: 3005 people with fever presented to CHWs during the study period
Exclusions: Pregnancy, symptoms suggestive of severe disease and prior study inclusion
within the previous 28 days
Interventions The intervention:
• Who was trained? CHWs
• How long they were trained for? One week
• What they were trained to do? Diagnose malaria in people presenting with fever
using RDTs and treat with ACT, refer people with danger signs
• How they were supervised? Supervised throughout the study but unclear
• Were the antimalarials given free? Yes
• Additional details: Community sensitization meetings were held prior to the study
The control group: CHWS diagnosed malaria using a clinical algorithm and treated with
ACT
Outcomes Outcomes included in this review
• Proportion of fever patients treated with ACT
• Mortality
Outcomes not included in this review
• Proportion of patients presenting within 24 hours of fever onset
• Referral rates up to day 7
• Compliance to treatment
Notes Country: Tanzania
Setting: Rural
Malaria endemicity: Holoendemic. The study was conducted during the peak malaria
transmission period
Study dates: March to August 2006
Study sponsor: Sida/SAREC
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Each of the 22 CHWs was assigned a
unique number which was noted on a lot-
tery ticket. 11 lottery tickets were then
picked blindly by one researcher from a box
after mixing.’
Allocation concealment (selection bias) Low risk See above.
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Mubi 2011 (Continued)
Baseline imbalance Low risk No differences in age, sex or duration of
fever are noted at baseline
Contamination Low risk CHWs working within the same villages
were randomized to intervention and con-
trol. Nomisuse of RDTs is reported during
the cross-over design and contamination is
unlikely
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Noblinding is described but this is unlikely
to have influenced the included outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk For the primary outcome (proportion of
fever cases prescribed ACT) no loss to fol-
low-up was reported
Loss of clusters Low risk No loss of clusters reported.
Selective reporting (reporting bias) Low risk No evidence of selective outcome report-
ing.
Other bias Low risk No other forms of bias identified.
Nsungwa-Sabiiti 2007
Methods Trial design: Controlled before-and-after study
Study areas: Two sub counties (Kyondo and Kitholhu) received the intervention and
were compared to a control site comparable in population size (Kyarumba)
Data collection: Cross sectional surveys at baseline and post intervention using cluster
randomized sampling
Length of follow-up: 17 to 22 months
Participants Target group: Children under the age of five years.
Sample size: At baseline 498 febrile children under five years were recruited into the
study, and at post intervention 587 children were recruited
Exclusions: None stated
Interventions The intervention:
• Who was trained? Community volunteers
• How long they were trained for? Three days
• What they were trained to do? Recognise illness symptoms, treat malaria with pre-
packaged CQ+SP, and refer to health facilities
• How they were supervised? District health team supervised the programme every
3 months
• Were the antimalarials provided free? Yes
• Additional details:
Antimalarials were given as pre-packaged CQ + SP labelled ’HOMAPAK’. Volunteers
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Nsungwa-Sabiiti 2007 (Continued)
also educated mothers about care seeking at home visits and through village meetings
Control: In control areas antimalarials could be accessed over the counter at pharmacies
or by attending health facilities
Outcomes Outcomes included in the review:
• Proportion of fevers treated with antimalarials
• Proportion of fevers treated with antimalarials within 24 hours of the onset of
illness
• Proportion of fevers treated with the recommended antimalarials
• Proportion of fevers treated with adequate dosage of antimalarials
• Proportion of fevers treated with adequate duration of antimalarials
Notes Country: Uganda
Setting: Rural, with 56% of the population living in absolute poverty
Malaria endemicity: Hyperendemic
Study dates: August 2002 to September 2004
Study sponsor: Department for Research Cooperation Makerere Univerity, Swedish In-
stitute
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomization.
Allocation concealment (selection bias) High risk Not applicable.
Baseline imbalance High risk Very few baseline data were presented.
There were substantial differences in the
use of antimalarials between intervention
and control areas at base-line which is likely
to confound the results
Contamination Low risk No evidence of contamination identified.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding is reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk The data were collected via cross-sec-
tional surveys using cluster-randomized
sampling. The same households were not
necessarily sampled pre- and post- inter-
vention
Loss of clusters Low risk Not applicable.
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Nsungwa-Sabiiti 2007 (Continued)
Selective reporting (reporting bias) Low risk No evidence of selective outcome reporting
was found.
Other bias Low risk We did not identify any other potential
source of bias.
Spencer 1987
Methods Trial design: Controlled before-and-after study
Study areas: Community divided into three operational areas; (A & B = Intervention, C
= Control)
Data collection: Pre and post intervention household survey
Length of follow-up: 12 months
Participants Target treatment group: Adults and children.
Sample size: Unclear
Exclusions: None stated
Interventions The intervention:
• Who was trained? literate volunteers who were young, female, married, educated,
religious and highly motivated to help their community.
• How long they were trained for? Not reported.
• What they were trained to do? Trained to give CQ ‘to every person who came for
treatment saying they had ‘malaria’ and to refer ill patients’.
• How they were supervised? Details unavailable. Volunteers recorded details on
each person and kept this as a permanent record.
• Were the antimalarials provided free? Yes
• Additional details: CQ was purchased from commercial sources using funds
supplied by the WHO and distributed to VHH’s. To replenish the VHH’s supply they
returned to clinic with their record book. Of note there was high level of presumptive
treatment with CQ in the community prior to the onset of the programme.
The control group: Community zone C was designated as the control group. The vol-
unteers were not supplied with CQ, but malaria treatment was available from the Sara-
didi community clinic, two Ministry of Health dispensaries in the areas and admission
hospital. CQ could also be purchased from small shops
Outcomes Outcomes included in the review:
• All-cause mortality
• Malaria specific mortality
• Prevalence of parasitaemia
Outcomes not included in the review:
• Perinatal mortality
• Fertility rates,
• Person consulted for treatment.
Notes Country: Kenya
Setting: Saradidi near Lake Victoria, Rural
Malaria endemicity: hyper to holoendemic area
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Spencer 1987 (Continued)
Study dates: 1981 to 1983
Study sponsor: Supported by WHO/UNDP and World Bank.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomization process, sites selected on
basis of development
Allocation concealment (selection bias) High risk Not applicable.
Baseline imbalance High risk High level of presumptive treatment with
CQ prior to intervention. Incomplete con-
trol group Data, Pre intervention data is
not available due to overlap with the inter-
vention and census dates
Contamination Unclear risk The authors did not discuss any steps taken
to reduce the risk of contamination
Blinding of outcome assessment (detection
bias)
All outcomes
High risk There was no blinding.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All data has been presented, however diffi-
cult to extrapolate actual values
Loss of clusters Low risk Not applicable.
Selective reporting (reporting bias) Low risk No evidence of selective outcome reporting
was found.
Other bias Low risk We did not identify any other potential
source of bias.
Staedke 2009
Methods Trial design: Cluster RCT
Unit of randomization: Household
Number of clusters: 325 households.
Data collection: Monthly diaries by mothers and questionnaires
Length of follow-up: 12 months
Participants Target treatment group: Children aged 1 to 6 years
Sample size: 437 children, 225 intervention versus 212 control group 1
Exclusions: Weight < 10 kg, serious chronic disease, intention to move out of study area,
history of serious adverse reaction to study drug, severe malnutrition or anaemia
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Interventions The intervention:
• Who was trained? Primary caregivers (usually mothers)
• How long they were trained for? Not stated
• What they were trained to do? Keep a diary about the health of their child, treat
fever with AL
• How they were supervised: Study personnel visited the household every month to
collect completed diaries and administer a questionnaire.
• Were the antimalarials given free? Yes
• Additional details:
Control group 1: Caregivers advised to continue with their current approach tomanaging
fevers
Control group 2: A non-randomized comparison with a hospital based cohort was also
reported. In this group children aged one to 10 received antimalarials only for micro-
scopically-confirmed malaria
Outcomes Outcomes included in the review:
• Deaths
• Proportion of fevers treated with an effective antimalarial within 24 hours of
onset of symptoms
• Proportion of fevers receiving any antimalarial
• Prevalence of parasitaemia
• Prevalence of anaemia
Outcomes not included in the review:
• Treatment incidence density (antimalarial treatments per person per year)
• Incidence of illness episodes
• Frequency of febrile episodes
• Incidence of hospital admissions (per person per year)
• Anaemia
• Mean haemoglobin concentration at end of study
• Occurrence of parasitaemia
• Palpable spleen
Notes Country: Uganda
Setting: Urban
Malaria endemicity: mesoendemic, perennial
Study dates: September 2005 to February 2007
Study sponsor: Gates Malaria Partnership
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “An independent projectmember, whohad
no further involvement in the rest of the
trial, prepared a computer-generated ran-
domization list”
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Staedke 2009 (Continued)
Allocation concealment (selection bias) Low risk “randomization numbers that correlated
with the assigned study interventions were
concealed in opaque envelopes”
Baseline imbalance Low risk The baseline characteristics between the in-
tervention and standard care armwere sim-
ilar
Contamination Unclear risk The potential for contamination is not
discussed by the study authors. However,
the prevalence of anaemia substantially
reduced in both treatment and control
groups during the study period. The rea-
sons for this are unclear but include con-
tamination or confounding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding is described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differential loss to follow-up (28 partic-
ipants out of 217 in the intervention group
and 32 out of 208 participants in the con-
trol group were lost to follow-up)
Loss of clusters Low risk No loss of clusters reported.
Selective reporting (reporting bias) Low risk No evidence of selective outcome reporting
was identified.
Other bias Low risk We did not identify any other potential
source of bias.
Yeboah-Antwi 2010
Methods Trial design: Cluster RCT
Unit of randomization: Community health posts (CHPs)
Number of clusters: 31 CHPs (15 in the intervention arm and 16 in the control arm)
Data collection: Baseline and post intervention household survey
Length of follow-up: 12 months
The authors adjusted for clustering
Participants Target treatment group: Children aged six months to 5 years
Sample size: 3,125 children (1,017 in the intervention arm and 2,108 in the control
arm)
Exclusions: None stated
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Yeboah-Antwi 2010 (Continued)
Interventions The intervention:
• Who was trained? CHWs
• How long they were trained for? Five days
• What they were trained to do? Manage febrile illness including testing for malaria
using an RDT, treat positive results with AL, and treat non-severe pneumonia
(increased respiratory rate) with amoxicillin
• How they were supervised? Monthly supervision by head nurse at the health centre
• Were the antimalarials given free? Yes
• Additional details:
Control: CHWs in control areas underwent the same training except for the use of
RDTs. All febrile children were treated with AL, and those with signs of pneumonia
were referred to the health facility, as per Ministry of Health policy
Outcomes Outcomes included in the review:
• Mortality
• Hospitalization
• The proportion of children with fever who received AL
• The proportion of participants with a negative RDT who received antimalarials
Outcomes not included in this review:
• Treatment failure; defined as presence of danger signs at day 5 to 7 (fever >37.
5°C, fast breathing, chest indrawing, need for additional antibiotics or antimalarials)
• The proportion of children with non-severe pneumonia who received prompt and
appropriate treatment
• Change in health-seeking behaviour
Notes Country: Zambia
Setting: Rural areas with poor road network
Malaria endemicity: Hyperendemic
Study dates: December 2007 to November 2008
Study sponsor: The United States Agency for International Development, President’s
Malaria Initiative
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Community health posts...were matched
in pairs according to the distance from the
health post. A random number generator
was used to assign one post in the pair to
the control arm,while thematchedpairwas
assigned to the intervention arm.”
Allocation concealment (selection bias) High risk Allocation concealment was not described.
Baseline imbalance High risk Baseline data were well presented. The pro-
portion of children up-to-date with im-
munizations was significantly lower in the
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Yeboah-Antwi 2010 (Continued)
intervention areas which could indicate
poorer access to health services
Contamination Low risk No evidence of contamination identified.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Noblinding is described but this is unlikely
to have affected the primary outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up was reported for the
primary outcome (proportion of children
presenting with fever prescribed ACT)
Loss of clusters Low risk No loss of clusters was reported.
Selective reporting (reporting bias) Low risk No evidence of selective outcome report-
ing.
Other bias Low risk We did not identify any other potential
source of bias.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abuya 2010 No relevant outcomes reported
Ahorlu 2009 This was an uncontrolled before-and-after study that evaluated the effects of intermittent preventive therapy in
the context of home management of malaria
Ajayi 2008a Assessment of accuracy of presumptive diagnoses
Ajayi 2008b No relevant outcomes reported
Ajayi 2008c No comparison between an intervention and a control.
Ansah 2010 The study had no intervention or programmewhich trained people to recognize and treat fevers with antimalarials
Bojang 2009 This study was designed to test intermittent preventive therapy in the context of home management of malaria
Chinbuah 2006 No comparison between an intervention and a control.
Dunyo 2000 The study tested the accuracy of malaria diagnosis at home versus health centre
Elmardi 2008 No comparison between an intervention and a control.
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Greenwood 1988 Not a home-based or community-based intervention trial.
Moir 1985 No comparison between an intervention and a control.
Ngasala 2011 Uncontrolled before-and-after study. This was a single arm study
Pagnoni 1997 No comparison between an intervention and a control.
Pence 2005 The intervention was not restricted to malaria treatment.
Sesay 2011 No comparison between an intervention and a control.
Sirima 2003 No comparison between an intervention and a control.
Skarbinski 2009 Not a home-based or community-based intervention trial.
Tiono 2008 No outcomes relevant to this review.
Characteristics of ongoing studies [ordered by study ID]
Ohnmar 2010
Trial name or title Community volunteers as agents for improving early diagnosis and appropriate treatment of malaria in Bago
Division, Myanmar
Methods Cluster randomized controlled trial
Participants Inclusion criteria: Subject older than six months with history of fever within one month, but not within 24
hours at the time of data collection in a malaria endemic village
Exclusion criteria: Fever within 24 hours
Age minimum: Six months
Age maximum: No limit
Gender: Both males and females
Interventions Training of community volunteers on the use of malaria RDT for diagnosis of malaria and treatment with
artemisinin based combination therapy (ACT) in remote villages where there is no health staff employed
Outcomes • Acceptability of volunteer system by health staff and community
• Mortality from malaria
• Period prevalence of malaria
Starting date 21/05/2009
Contact information Dr Ohnmar
Research Scientist
Epidemiology Research Division
Department of Medical Research (Lower Myanmar)
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No.5, Ziwaka Road, Dagon PO,
Yangon, Myanmar
Notes Sponsor: World Health Organization Regional Office for the South-East Asia - UNICEF/UNDP/World
Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) Small Grants Pro-
gramme (WHO/SEARO-TDR Small Grants Programme)
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D A T A A N D A N A L Y S E S
Comparison 1. Home- or community-based programmes versus facility-based care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Baseline 1 13677 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.96, 1.29]
1.2 At follow-up 1 13677 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.44, 0.77]
2 Parasitaemia prevalence - (with
sensitivity analysis)
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 At baseline - Not adjusted
for cluster design
2 1515 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.98, 1.09]
2.2 At follow-up - Not
adjusted for cluster design
2 1371 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.11, 2.61]
2.3 Adjusted for cluster design
using ICC = 0.01
2 935 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.10, 2.70]
2.4 Adjusted for cluster design
using ICC = 0.05
2 572 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.09, 3.05]
2.5 Adjusted for cluster design
using ICC = 0.10
2 477 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.08, 3.43]
3 Anaemia - (with sensitivity
analysis)
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 At baseline - Not adjusted
for clustering
3 3230 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.88, 1.71]
3.2 At follow-up - Not
adjusted for clustering
3 3540 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.70, 2.51]
3.3 Adjusted for clustering
using ICC = 0.01
3 1622 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.81, 1.64]
3.4 Adjusted for clustering
using ICC = 0.05
3 756 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.66, 1.93]
3.5 Adjusted for clustering
using ICC = 0.10
3 573 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.56, 2.01]
4 Fever episodes receiving prompt
and effective treatment with an
antimalarial - (with sensitivity
analysis)
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 At baseline - Not adjusted
for cluster design
1 766 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.46, 1.59]
4.2 At follow-up - Not
adjusted for cluster design
2 2193 Risk Ratio (M-H, Random, 95% CI) 4.69 [1.00, 22.07]
4.3 Adjusted for cluster design
using ICC = 0.01
2 1923 Risk Ratio (M-H, Random, 95% CI) 4.69 [1.00, 21.93]
4.4 Adjusted for cluster design
using ICC = 0.05
2 1472 Risk Ratio (M-H, Random, 95% CI) 4.70 [1.06, 20.92]
4.5 Adjusted for cluster design
using ICC = 0.10
2 1216 Risk Ratio (M-H, Random, 95% CI) 4.82 [1.07, 21.80]
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5 Fever episodes receiving
treatment with an antimalarial
- (with sensitivity analysis)
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 At baseline - Not adjusted
for cluster design
2 1077 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.45, 0.70]
5.2 At follow-up - Not
adjusted for cluster design
3 2716 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [1.26, 1.40]
5.3 Adjusted for cluster design
using ICC = 0.01
3 2299 Risk Ratio (M-H, Fixed, 95% CI) 1.34 [1.27, 1.41]
5.4 Adjusted for cluster design
using ICC = 0.05
3 1648 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [1.27, 1.44]
5.5 Adjusted for cluster design
using ICC = 0.10
3 1322 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [1.26, 1.45]
Comparison 2. Home- or community-based programmes using RDTs versus clinical diagnosis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 At follow-up - Not
adjusted for cluster design
2 6055 Risk Ratio (M-H, Random, 95% CI) 3.51 [0.68, 18.22]
2 Hospitalization 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 At follow-up - Not
adjusted for cluster design
1 3125 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.20, 1.79]
3 Referrals for further care 1 Risk Ratio (Random, 95% CI) Subtotals only
3.1 At follow-up - Adjusted
for cluster design
1 2930 Risk Ratio (Random, 95% CI) 1.89 [1.35, 2.65]
4 Treatment failure at day 7 2 Risk Ratio (Random, 95% CI) Subtotals only
4.1 At follow-up - Adjusted
for cluster design
2 5994 Risk Ratio (Random, 95% CI) 1.23 [0.40, 3.81]
5 Fever episodes receiving prompt
and effective treatment with an
antimalarial
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 At follow-up - Not
adjusted for cluster design
2 5977 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.18, 0.84]
5.2 Adjusted for clustering
using ICC = 0.05
2 904 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.18, 0.86]
5.3 Adjusted for clustering
using ICC = 0.10
2 490 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.18, 0.87]
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Analysis 1.1. Comparison 1 Home- or community-based programmes versus facility-based care, Outcome
1 All-cause mortality.
Review: Home- or community-based programmes for treating malaria
Comparison: 1 Home- or community-based programmes versus facility-based care
Outcome: 1 All-cause mortality
Study or subgroup Programmes Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Baseline
Kidane 2000 (1) 6/482 5/476 1.5 % 1.19 [ 0.36, 3.86 ]
Kidane 2000 6/449 5/376 1.5 % 1.00 [ 0.31, 3.27 ]
Kidane 2000 5/491 7/852 1.6 % 1.24 [ 0.40, 3.88 ]
Kidane 2000 18/654 11/731 3.9 % 1.83 [ 0.87, 3.84 ]
Kidane 2000 16/417 13/560 4.1 % 1.65 [ 0.80, 3.40 ]
Kidane 2000 18/632 13/386 4.4 % 0.85 [ 0.42, 1.71 ]
Kidane 2000 16/400 28/703 5.9 % 1.00 [ 0.55, 1.83 ]
Kidane 2000 39/644 40/577 11.8 % 0.87 [ 0.57, 1.34 ]
Kidane 2000 47/528 45/627 14.0 % 1.24 [ 0.84, 1.84 ]
Kidane 2000 48/812 51/1027 14.6 % 1.19 [ 0.81, 1.75 ]
Kidane 2000 57/361 55/451 18.2 % 1.29 [ 0.92, 1.83 ]
Kidane 2000 55/513 63/528 18.5 % 0.90 [ 0.64, 1.26 ]
Subtotal (95% CI) 6383 7294 100.0 % 1.12 [ 0.96, 1.29 ]
Total events: 331 (Programmes), 336 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.56, df = 11 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
2 At follow-up
Kidane 2000 (2) 10/482 17/476 6.8 % 0.58 [ 0.27, 1.26 ]
Kidane 2000 10/632 31/386 7.4 % 0.20 [ 0.10, 0.40 ]
Kidane 2000 11/400 29/703 7.6 % 0.67 [ 0.34, 1.32 ]
Kidane 2000 10/528 42/627 7.7 % 0.28 [ 0.14, 0.56 ]
Kidane 2000 12/449 25/376 7.7 % 0.40 [ 0.20, 0.79 ]
Kidane 2000 16/417 20/560 8.0 % 1.07 [ 0.56, 2.05 ]
Kidane 2000 14/361 24/451 8.1 % 0.73 [ 0.38, 1.39 ]
Kidane 2000 17/513 32/528 8.8 % 0.55 [ 0.31, 0.97 ]
0.1 0.2 0.5 1 2 5 10
Favours Programmes Favours Control
(Continued . . . )
44Home- or community-based programmes for treating malaria (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Programmes Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kidane 2000 16/491 41/852 8.9 % 0.68 [ 0.38, 1.19 ]
Kidane 2000 28/654 26/731 9.5 % 1.20 [ 0.71, 2.03 ]
Kidane 2000 21/812 43/1027 9.6 % 0.62 [ 0.37, 1.03 ]
Kidane 2000 25/644 36/577 9.8 % 0.62 [ 0.38, 1.02 ]
Subtotal (95% CI) 6383 7294 100.0 % 0.58 [ 0.44, 0.77 ]
Total events: 190 (Programmes), 366 (Control)
Heterogeneity: Tau2 = 0.14; Chi2 = 26.51, df = 11 (P = 0.01); I2 =59%
Test for overall effect: Z = 3.85 (P = 0.00012)
0.1 0.2 0.5 1 2 5 10
Favours Programmes Favours Control
(1) Kidane 2000: The 12 matched pairs are analysed seperately to account for clustering.
(2) Kidane 2000: Conducted in rural villages in Ethiopia.
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Analysis 1.2. Comparison 1 Home- or community-based programmes versus facility-based care, Outcome
2 Parasitaemia prevalence - (with sensitivity analysis).
Review: Home- or community-based programmes for treating malaria
Comparison: 1 Home- or community-based programmes versus facility-based care
Outcome: 2 Parasitaemia prevalence - (with sensitivity analysis)
Study or subgroup Programmes Standard care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At baseline - Not adjusted for cluster design
Kouyate 2008 455/542 438/541 99.2 % 1.04 [ 0.98, 1.10 ]
Staedke 2009 18/222 18/210 0.8 % 0.95 [ 0.51, 1.77 ]
Subtotal (95% CI) 764 751 100.0 % 1.04 [ 0.98, 1.09 ]
Total events: 473 (Programmes), 456 (Standard care)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
2 At follow-up - Not adjusted for cluster design
Kouyate 2008 379/496 366/510 55.5 % 1.06 [ 0.99, 1.15 ]
Staedke 2009 4/189 17/176 44.5 % 0.22 [ 0.08, 0.64 ]
Subtotal (95% CI) 685 686 100.0 % 0.53 [ 0.11, 2.61 ]
Total events: 383 (Programmes), 383 (Standard care)
Heterogeneity: Tau2 = 1.20; Chi2 = 9.01, df = 1 (P = 0.003); I2 =89%
Test for overall effect: Z = 0.79 (P = 0.43)
3 Adjusted for cluster design using ICC = 0.01
Kouyate 2008 215/281 208/289 55.2 % 1.06 [ 0.96, 1.17 ]
Staedke 2009 4/189 17/176 44.8 % 0.22 [ 0.08, 0.64 ]
Subtotal (95% CI) 470 465 100.0 % 0.52 [ 0.10, 2.70 ]
Total events: 219 (Programmes), 225 (Standard care)
Heterogeneity: Tau2 = 1.26; Chi2 = 9.42, df = 1 (P = 0.002); I2 =89%
Test for overall effect: Z = 0.77 (P = 0.44)
4 Adjusted for cluster design using ICC = 0.05
Kouyate 2008 79/103 76/106 54.4 % 1.07 [ 0.91, 1.26 ]
Staedke 2009 4/188 17/175 45.6 % 0.22 [ 0.08, 0.64 ]
Subtotal (95% CI) 291 281 100.0 % 0.52 [ 0.09, 3.05 ]
Total events: 83 (Programmes), 93 (Standard care)
Heterogeneity: Tau2 = 1.50; Chi2 = 10.83, df = 1 (P = 0.001); I2 =91%
Test for overall effect: Z = 0.72 (P = 0.47)
5 Adjusted for cluster design using ICC = 0.10
Kouyate 2008 44/57 42/59 53.8 % 1.08 [ 0.87, 1.34 ]
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(. . . Continued)
Study or subgroup Programmes Standard care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Staedke 2009 4/187 17/174 46.2 % 0.22 [ 0.08, 0.64 ]
Subtotal (95% CI) 244 233 100.0 % 0.52 [ 0.08, 3.43 ]
Total events: 48 (Programmes), 59 (Standard care)
Heterogeneity: Tau2 = 1.72; Chi2 = 12.09, df = 1 (P = 0.00051); I2 =92%
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Chi2 = 2.44, df = 4 (P = 0.66), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours Programs Favours Standard care
Analysis 1.3. Comparison 1 Home- or community-based programmes versus facility-based care, Outcome
3 Anaemia - (with sensitivity analysis).
Review: Home- or community-based programmes for treating malaria
Comparison: 1 Home- or community-based programmes versus facility-based care
Outcome: 3 Anaemia - (with sensitivity analysis)
Study or subgroup Programmes Standard care Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At baseline - Not adjusted for clustering
Eriksen 2010 (1) 406/925 243/790 1.43 [ 1.26, 1.62 ]
Kouyate 2008 (2) 152/542 162/541 0.94 [ 0.78, 1.13 ]
Staedke 2009 (3) 36/222 23/210 1.48 [ 0.91, 2.41 ]
Subtotal (95% CI) 1689 1541 1.23 [ 0.88, 1.71 ]
Total events: 594 (Programmes), 428 (Standard care)
Heterogeneity: Tau2 = 0.07; Chi2 = 13.80, df = 2 (P = 0.001); I2 =86%
Test for overall effect: Z = 1.21 (P = 0.23)
2 At follow-up - Not adjusted for clustering
Eriksen 2010 8/982 2/1187 4.84 [ 1.03, 22.72 ]
Kouyate 2008 83/496 74/510 1.15 [ 0.86, 1.54 ]
Staedke 2009 7/189 7/176 0.93 [ 0.33, 2.60 ]
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Study or subgroup Programmes Standard care Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 1667 1873 1.33 [ 0.70, 2.51 ]
Total events: 98 (Programmes), 83 (Standard care)
Heterogeneity: Tau2 = 0.15; Chi2 = 3.44, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 0.88 (P = 0.38)
3 Adjusted for clustering using ICC = 0.01
Eriksen 2010 3/311 1/376 3.63 [ 0.38, 34.69 ]
Kouyate 2008 47/281 42/289 1.15 [ 0.79, 1.69 ]
Staedke 2009 7/189 7/176 0.93 [ 0.33, 2.60 ]
Subtotal (95% CI) 781 841 1.15 [ 0.81, 1.64 ]
Total events: 57 (Programmes), 50 (Standard care)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.16, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.43)
4 Adjusted for clustering using ICC = 0.05
Eriksen 2010 1/83 0/101 3.64 [ 0.15, 88.26 ]
Kouyate 2008 17/103 15/106 1.17 [ 0.62, 2.21 ]
Staedke 2009 7/188 7/175 0.93 [ 0.33, 2.60 ]
Subtotal (95% CI) 374 382 1.13 [ 0.66, 1.93 ]
Total events: 25 (Programmes), 22 (Standard care)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.66, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.65)
5 Adjusted for clustering using ICC = 0.10
Eriksen 2010 0/43 0/53 0.0 [ 0.0, 0.0 ]
Kouyate 2008 10/57 9/59 1.15 [ 0.50, 2.62 ]
Staedke 2009 7/187 7/174 0.93 [ 0.33, 2.60 ]
Subtotal (95% CI) 287 286 1.06 [ 0.56, 2.01 ]
Total events: 17 (Programmes), 16 (Standard care)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Chi2 = 0.34, df = 4 (P = 0.99), I2 =0.0%
0.01 0.1 1 10 100
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(1) Eriksen 2010 defined anaemia as Haemoglobin < 8g/dL
(2) Kouyate 2008 defined anaemia as haematocrit < 24%
(3) Staedke 2009 defined anaemia as haemoglobin < 10 g/dL
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Analysis 1.4. Comparison 1 Home- or community-based programmes versus facility-based care, Outcome
4 Fever episodes receiving prompt and effective treatment with an antimalarial - (with sensitivity analysis).
Review: Home- or community-based programmes for treating malaria
Comparison: 1 Home- or community-based programmes versus facility-based care
Outcome: 4 Fever episodes receiving prompt and effective treatment with an antimalarial - (with sensitivity analysis)
Study or subgroup Programmes Standard care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At baseline - Not adjusted for cluster design
Kangwana 2011 (1) 19/413 19/353 100.0 % 0.85 [ 0.46, 1.59 ]
Subtotal (95% CI) 413 353 100.0 % 0.85 [ 0.46, 1.59 ]
Total events: 19 (Programmes), 19 (Standard care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
2 At follow-up - Not adjusted for cluster design
Kangwana 2011 (2) 187/417 68/344 50.4 % 2.27 [ 1.79, 2.88 ]
Staedke 2009 (3) 444/862 30/570 49.6 % 9.79 [ 6.87, 13.95 ]
Subtotal (95% CI) 1279 914 100.0 % 4.69 [ 1.00, 22.07 ]
Total events: 631 (Programmes), 98 (Standard care)
Heterogeneity: Tau2 = 1.23; Chi2 = 52.70, df = 1 (P<0.00001); I2 =98%
Test for overall effect: Z = 1.95 (P = 0.051)
3 Adjusted for cluster design using ICC = 0.01
Kangwana 2011 132/295 48/243 50.3 % 2.27 [ 1.71, 3.01 ]
Staedke 2009 429/834 29/551 49.7 % 9.77 [ 6.82, 14.01 ]
Subtotal (95% CI) 1129 794 100.0 % 4.69 [ 1.00, 21.93 ]
Total events: 561 (Programmes), 77 (Standard care)
Heterogeneity: Tau2 = 1.21; Chi2 = 45.31, df = 1 (P<0.00001); I2 =98%
Test for overall effect: Z = 1.96 (P = 0.050)
4 Adjusted for cluster design using ICC = 0.05
Kangwana 2011 61/136 22/112 49.8 % 2.28 [ 1.50, 3.47 ]
Staedke 2009 379/737 26/487 50.2 % 9.63 [ 6.58, 14.09 ]
Subtotal (95% CI) 873 599 100.0 % 4.70 [ 1.06, 20.92 ]
Total events: 440 (Programmes), 48 (Standard care)
Heterogeneity: Tau2 = 1.12; Chi2 = 27.87, df = 1 (P<0.00001); I2 =96%
Test for overall effect: Z = 2.03 (P = 0.042)
5 Adjusted for cluster design using ICC = 0.10
Kangwana 2011 36/81 13/67 49.3 % 2.29 [ 1.33, 3.95 ]
Staedke 2009 331/643 22/425 50.7 % 9.94 [ 6.57, 15.04 ]
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(. . . Continued)
Study or subgroup Programmes Standard care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 724 492 100.0 % 4.82 [ 1.07, 21.80 ]
Total events: 367 (Programmes), 35 (Standard care)
Heterogeneity: Tau2 = 1.12; Chi2 = 19.43, df = 1 (P = 0.00001); I2 =95%
Test for overall effect: Z = 2.04 (P = 0.041)
Test for subgroup differences: Chi2 = 11.65, df = 4 (P = 0.02), I2 =66%
0.01 0.1 1 10 100
Favours Standard care Favours Programmes
(1) Baseline data for Staedke 2009 were not provided
(2) Kangwana 2011 reports febrile episodes treated with AL within 48 hrs of fever onset
(3) Staedke 2009 reports febrile episodes treated with CQ+SP, Quinine or an ACT within 24 hrs of fever onset
Analysis 1.5. Comparison 1 Home- or community-based programmes versus facility-based care, Outcome
5 Fever episodes receiving treatment with an antimalarial - (with sensitivity analysis).
Review: Home- or community-based programmes for treating malaria
Comparison: 1 Home- or community-based programmes versus facility-based care
Outcome: 5 Fever episodes receiving treatment with an antimalarial - (with sensitivity analysis)
Study or subgroup Programmes Standard care Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At baseline - Not adjusted for cluster design
Kangwana 2011 (1) 0/413 0/353 0.0 [ 0.0, 0.0 ]
Kouyate 2008 66/179 87/132 0.56 [ 0.45, 0.70 ]
Subtotal (95% CI) 592 485 0.56 [ 0.45, 0.70 ]
Total events: 66 (Programmes), 87 (Standard care)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 5.00 (P < 0.00001)
2 At follow-up - Not adjusted for cluster design
Kangwana 2011 (2) 267/417 173/344 1.27 [ 1.12, 1.45 ]
Kouyate 2008 (3) 208/241 191/282 1.27 [ 1.16, 1.40 ]
Staedke 2009 (4) 764/862 367/570 1.38 [ 1.29, 1.47 ]
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Study or subgroup Programmes Standard care Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 1520 1196 1.33 [ 1.26, 1.40 ]
Total events: 1239 (Programmes), 731 (Standard care)
Heterogeneity: Chi2 = 2.29, df = 2 (P = 0.32); I2 =13%
Test for overall effect: Z = 10.96 (P < 0.00001)
3 Adjusted for cluster design using ICC = 0.01
Kangwana 2011 189/295 122/243 1.28 [ 1.10, 1.48 ]
Kouyate 2008 149/173 137/203 1.28 [ 1.14, 1.43 ]
Staedke 2009 739/834 355/551 1.38 [ 1.29, 1.47 ]
Subtotal (95% CI) 1302 997 1.34 [ 1.27, 1.41 ]
Total events: 1077 (Programmes), 614 (Standard care)
Heterogeneity: Chi2 = 1.71, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 10.41 (P < 0.00001)
4 Adjusted for cluster design using ICC = 0.05
Kangwana 2011 87/136 56/112 1.28 [ 1.02, 1.60 ]
Kouyate 2008 70/81 64/95 1.28 [ 1.09, 1.51 ]
Staedke 2009 653/737 314/487 1.37 [ 1.28, 1.48 ]
Subtotal (95% CI) 954 694 1.35 [ 1.27, 1.44 ]
Total events: 810 (Programmes), 434 (Standard care)
Heterogeneity: Chi2 = 0.83, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 9.32 (P < 0.00001)
5 Adjusted for cluster design using ICC = 0.10
Kangwana 2011 52/81 34/67 1.27 [ 0.95, 1.68 ]
Kouyate 2008 42/49 39/57 1.25 [ 1.02, 1.55 ]
Staedke 2009 570/643 274/425 1.37 [ 1.27, 1.48 ]
Subtotal (95% CI) 773 549 1.35 [ 1.26, 1.45 ]
Total events: 664 (Programmes), 347 (Standard care)
Heterogeneity: Chi2 = 0.90, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 8.49 (P < 0.00001)
Test for subgroup differences: Chi2 = 56.00, df = 4 (P = 0.00), I2 =93%
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(1) Baseline data for Staedke 2009 were not provided
(2) Kangwana 2011 reports febrile episodes treated with any antimalarial
(3) Kouyate 2008 reports febrile episodes within the last 2 days treated with CQ
(4) Staedke 2009 reports febrile episodes treated with any antimalarial
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Analysis 2.1. Comparison 2 Home- or community-based programmes using RDTs versus clinical diagnosis,
Outcome 1 All-cause mortality.
Review: Home- or community-based programmes for treating malaria
Comparison: 2 Home- or community-based programmes using RDTs versus clinical diagnosis
Outcome: 1 All-cause mortality
Study or subgroup RDT diagnosis Clinical diagnosis Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At follow-up - Not adjusted for cluster design
Mubi 2011 3/1457 1/1473 52.9 % 3.03 [ 0.32, 29.12 ]
Yeboah-Antwi 2010 2/1017 1/2108 47.1 % 4.15 [ 0.38, 45.66 ]
Subtotal (95% CI) 2474 3581 100.0 % 3.51 [ 0.68, 18.22 ]
Total events: 5 (RDT diagnosis), 2 (Clinical diagnosis)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
0.01 0.1 1 10 100
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Analysis 2.2. Comparison 2 Home- or community-based programmes using RDTs versus clinical diagnosis,
Outcome 2 Hospitalization.
Review: Home- or community-based programmes for treating malaria
Comparison: 2 Home- or community-based programmes using RDTs versus clinical diagnosis
Outcome: 2 Hospitalization
Study or subgroup RDT diagnosis Clinical diagnosis Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At follow-up - Not adjusted for cluster design
Yeboah-Antwi 2010 4/1017 14/2108 100.0 % 0.59 [ 0.20, 1.79 ]
Subtotal (95% CI) 1017 2108 100.0 % 0.59 [ 0.20, 1.79 ]
Total events: 4 (RDT diagnosis), 14 (Clinical diagnosis)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
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Analysis 2.3. Comparison 2 Home- or community-based programmes using RDTs versus clinical diagnosis,
Outcome 3 Referrals for further care.
Review: Home- or community-based programmes for treating malaria
Comparison: 2 Home- or community-based programmes using RDTs versus clinical diagnosis
Outcome: 3 Referrals for further care
Study or subgroup RDT diagnosis Clinical diagnosis log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 At follow-up - Adjusted for cluster design
Mubi 2011 (1) 1457 0.63671627 (0.17241978) 1473 100.0 % 1.89 [ 1.35, 2.65 ]
Subtotal (95% CI) 100.0 % 1.89 [ 1.35, 2.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.69 (P = 0.00022)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours RDT diagnosis Favours Clinical diagnosi
(1) Mubi 2011: This data has been converted from the cluster adjusted Odds Ratio presented in the original paper
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Analysis 2.4. Comparison 2 Home- or community-based programmes using RDTs versus clinical diagnosis,
Outcome 4 Treatment failure at day 7.
Review: Home- or community-based programmes for treating malaria
Comparison: 2 Home- or community-based programmes using RDTs versus clinical diagnosis
Outcome: 4 Treatment failure at day 7
Study or subgroup RDT diagnosis Clinical diagnosis log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 At follow-up - Adjusted for cluster design
Mubi 2011 (1) 1411 0.76546784 (0.18426599) 1458 51.8 % 2.15 [ 1.50, 3.09 ]
Yeboah-Antwi 2010 (2) 1017 2108 -0.3856625 (0.2845821) 48.2 % 0.68 [ 0.39, 1.19 ]
Subtotal (95% CI) 100.0 % 1.23 [ 0.40, 3.81 ]
Heterogeneity: Tau2 = 0.61; Chi2 = 11.53, df = 1 (P = 0.00069); I2 =91%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours RDT diagnosis Favours Clinical diagnosi
(1) Mubi 2011: This data has been converted from the cluster adjusted Odds Ratio presented in the original paper
(2) Yeboah-Antwi 2011: This data has been converted from the cluster adjusted Odds Ratio presented in the original paper
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Analysis 2.5. Comparison 2 Home- or community-based programmes using RDTs versus clinical diagnosis,
Outcome 5 Fever episodes receiving prompt and effective treatment with an antimalarial.
Review: Home- or community-based programmes for treating malaria
Comparison: 2 Home- or community-based programmes using RDTs versus clinical diagnosis
Outcome: 5 Fever episodes receiving prompt and effective treatment with an antimalarial
Study or subgroup RDT diagnosis Clinical diagnosis Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At follow-up - Not adjusted for cluster design
Mubi 2011 775/1457 1422/1473 50.2 % 0.55 [ 0.52, 0.58 ]
Yeboah-Antwi 2010 265/963 2066/2084 49.8 % 0.28 [ 0.25, 0.31 ]
Subtotal (95% CI) 2420 3557 100.0 % 0.39 [ 0.18, 0.84 ]
Total events: 1040 (RDT diagnosis), 3488 (Clinical diagnosis)
Heterogeneity: Tau2 = 0.30; Chi2 = 180.26, df = 1 (P<0.00001); I2 =99%
Test for overall effect: Z = 2.41 (P = 0.016)
2 Adjusted for clustering using ICC = 0.05
Mubi 2011 102/191 187/194 50.9 % 0.55 [ 0.48, 0.63 ]
Yeboah-Antwi 2010 45/164 352/355 49.1 % 0.28 [ 0.22, 0.35 ]
Subtotal (95% CI) 355 549 100.0 % 0.39 [ 0.18, 0.86 ]
Total events: 147 (RDT diagnosis), 539 (Clinical diagnosis)
Heterogeneity: Tau2 = 0.30; Chi2 = 30.06, df = 1 (P<0.00001); I2 =97%
Test for overall effect: Z = 2.35 (P = 0.019)
3 Adjusted for clustering using ICC = 0.10
Mubi 2011 55/102 100/104 51.6 % 0.56 [ 0.47, 0.67 ]
Yeboah-Antwi 2010 25/90 193/194 48.4 % 0.28 [ 0.20, 0.39 ]
Subtotal (95% CI) 192 298 100.0 % 0.40 [ 0.18, 0.87 ]
Total events: 80 (RDT diagnosis), 293 (Clinical diagnosis)
Heterogeneity: Tau2 = 0.30; Chi2 = 16.85, df = 1 (P = 0.00004); I2 =94%
Test for overall effect: Z = 2.30 (P = 0.021)
Test for subgroup differences: Chi2 = 0.00, df = 2 (P = 1.00), I2 =0.0%
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A D D I T I O N A L T A B L E S
Table 1. Summary of trials comparing home-or community-based interventions with facility- based care
Study ID Study De-
sign
Country
(setting)
Who was
trained?
How long
was the
training?
What were
they trained
to do?
Were drugs
given free?
How were
they super-
vised?
Additional
comments
Kangwana
2011
Cluster-
RCT
Kenya
(Rural)
Retail outlet
staff
1 day Treat clinical
malaria with
AL
Referral cri-
teria
Subsidized Retail staff
kept records
of prescrip-
tion.
Study staff
visited after
3 months.
Extensive
social mar-
keting
of branded
AL was con-
ducted
among the
community
Eriksen
2010
Cluster-
RCT
Tanzania
(Unclear)
Health
workers
7 days Malaria case
manage-
ment
Yes Health
workers vis-
ited women
leaders every
2 weeks.
Commu-
nity aware-
ness activi-
ties also took
place.
Women
leaders were
paid $20 per
month.
Women
leaders
7 days Treat clinical
malaria with
SP
Referral cri-
teria
Staedke
2009
Cluster-
RCT
Uganda
(Urban)
Mothers Unclear Treat fever
with AL
Yes Study
personnel
visited every
month.
Kouyate
2008
Cluster-
RCT
Burkina
Faso
(Rural)
Nurses 5 days Malaria case
manage-
ment
Subsidized Nurses vis-
ited women
group lead-
ers monthly.
Study
personnel
visited
monthly.
Drugs sup-
plied free to
women
group lead-
ers
who charged
mothers a
small fee
Women
group lead-
ers
2 days Treat clinical
malaria with
CQ
Mothers ½ day Take
children
with fever to
women
leaders
Kidane
2000
Cluster-
RCT
Ethiopia
(Rural)
Mother co-
ordinators
2 months Referral cri-
teria
To train
mothers to
treat clinical
malaria
Yes Field super-
visors visited
the mother
co-or-
dinators 4 to
The mother
co-or-
dinators col-
lected
the data on
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Table 1. Summary of trials comparing home-or community-based interventions with facility- based care (Continued)
6 times per
month and
di-
rectly super-
vised a sam-
ple of moth-
ers.
death.
Mothers Unclear Treat clinical
malaria with
CQ
Nsungwa-
Sabiiti
2007
CBA Uganda
(Rural)
Community
volunteers
3 days Treat fever
with
CQ+SP, and
referral cri-
teria
Yes The district
health team
su-
pervised the
programme
every 3
months
Volunteers
also edu-
cated moth-
ers about
care-seeking
at home vis-
its and
village meet-
ings
Delacol-
lette
1996
CBA DRC
(Rural)
Literate vol-
unteers
2 weeks Treat fever
with CQ
Subsidized Closely su-
pervised by
nurses from
the health
facility.
Volunteers
received
a small mon-
etary incen-
tive.
Spencer
1987
CBA Kenya
(Rural)
CHWs Unclear Treat fever
with CQ
Yes Unclear
RCT = Randomized controlled trial, CBA = controlled before-and-after study, DRC = Democratic Republic of Congo, CHW =
community health worker, SP = sulphadoxine-pyrimethamine, CQ = chloroquine, AL = artemether-lumefantrine, RDT = rapid
diagnostic test
Table 2. Summary of trials comparing home- or community-based programmes using RDT diagnosis versus clinical diagnosis
Study ID Study De-
sign
Country
(setting)
Who was
trained?
How long
was the
training?
What were
they trained
to do?
Were drugs
given free?
How were
they super-
vised?
Additional
comments
Yeboah-
Antwi 2010
Cluster-
RCT
Zambia
(Rural)
Commu-
nity health
Workers
5 days Treat fever +
positive
RDT with
AL
Yes Monthly su-
pervision by
the head
nurse of
each health
centre
In the con-
trol
arm, CHWs
treated all
fevers with
AL.
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Table 2. Summary of trials comparing home- or community-based programmes using RDT diagnosis versus clinical diagnosis
(Continued)
Mubi 2011 Cross-over
cluster-RCT
Tanzania
(Rural)
Community
health work-
ers
7 days Treat fever +
positive
RDT with
AL
Yes Supervised
throughout
the
study but no
details pro-
vided
In the con-
trol
arm, CHWs
treated all
fevers with
AL.
RCT = Randomized controlled trial, AL = artemether-lumefantrine, RDT = rapid diagnostic test, CHW = community health workers
Table 3. Summary of results from cluster-RCTs comparing home- or community-based programmes with facility-based care
Outcome Study ID
Number of events/number of participants
(percentage) Comment
Home- or community-based
programmes
Facility-based care
Baseline Follow-up Difference Baseline Follow-up Difference
All-cause
mortality
Kidane
2000
- 190/6383
(29.8%)
- - 366/7294
(50.2%)
- Rate ratio 0.
59, 95%CI0.
50 to 0.711
Staedke
2009
1/189
(0.5%)
1/176
(0.5%)
2
Malaria-
specific
mortality
Kidane
2000
13/70
(18.6%)
68/120
(56.7%)
Deter-
mined by ver-
bal autopsy3
Hospital-
ization
Staedke
2009
- 25/189
(13.2%)
- 40/176
(22.7%)
Rate ratio 0.
63, 95%CI0.
35 to 1.17
Para-
sitaemia
Staedke
2009
- 4/189
(1.8%)
- - 17/176
(9.7%)
- RR
0.21, 95% CI
0.07 to 0.64
Kouyate
2008
455/542
(84%)
379/496
(76%)
-8% 438/541
(81%)
366/510
(72%)
-9% P = 0.05
Anaemia Eriksen
2010
406/925
(43.9%)
8/982
(0.8%)
-43.1% 243/790
(30.8%
2/1187
(0.2%)
-30.6%
Staedke
2009
36/222
(16%)
7/189
(4%)
-12% 23/210
(11%)
7/176
(4%)
-7%
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Table 3. Summary of results from cluster-RCTs comparing home- or community-based programmes with facility-based care
(Continued)
Kouyate
2008
152/542
(28%)
83/496
(17%)
-11% 162/541
(30%)
74/510
(15%)
-15% P = 0.32
Fever
episodes re-
ceiving
prompt and
effective
treatment
with anti-
malarials
Kangwana
20114
N/R
(4.7%)
N/R
(44.9%)
+40.2% N/R
(5.3%)
N/R
(19.9%)
+14.6% P = 0.0001
Staedke
20095
- 444/862
(51.5%)
- - 30/570
(5.2%)
- P < 0.0001
Fever
episodes
treated with
any anti-
malarial
Kangwana
2011
N/R
(45.5%)
N/R
(64.0%)
+18.5% N/R
(38.9%)
N/R
(50.3%)
11.4% P = 0.0074
Staedke
2009
- 764/862
(88.7%)
- - 367/570
(64.4%)
- P < 0.0001
Kouyate
20086
66/179
(36.9%)
208/241
(86.3%)
- 87/132
(65.9%)
191/282
(67.7%)
- P = not re-
ported
RR = risk ratio, N/R = not reported
1 This result was not adjusted for clustering so the 95% CI will be artificially narrow.
2 Staedke 2009 was not adequately powered to look for an effect on mortality.
3 Verbal autopsy was only conducted on one third of all deaths.
4 In Kangwana 2011 ’prompt and effective treatment’ is defined as any brand of AL on the same day or following day.
5 In Staedke 2009 ’prompt and effective treatment’ is defined as CQ+SP, or quinine, or an artemisinin within 24 hours.
6 In Kouyate 2008 there is a large baseline imbalance in health seeking behaviour between the two groups.
Table 4. Additional results from non-randomized studies for malaria-specific mortality
Outcome Study ID Study design Age group Time period Home- or
community-
based
programmes*
Control* Comment
Malaria-
specific mor-
tality
Delacollette
1996
CBA All Aug 85 to Mar
86 (pre-inter-
vention)
17 (102,410) 27 (116,541) Mortal-
ity per 10,000
patient months
(number of pa-
tient months
observed)
Apr 86 to Jul
86 (early inter-
vention)
21 (51,887) 35 (59,490)
Aug 86 to Mar
87 (full inter-
vention)
14 (103,704) 27 (120,879)
59Home- or community-based programmes for treating malaria (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 4. Additional results from non-randomized studies for malaria-specific mortality (Continued)
Apr 87 to Jul
87 (full inter-
vention)
32 (21,944) 22 (36,530)
Spencer 1987 CBA < 1 year May 81 to
April 82 (pre-
intervention)
6.8 (8) - Mortality
per 1000 popu-
lation (number
of deaths).
1 to 4 years Sept 82 to Aug
83 (during in-
tervention)
7.4 (10) 4.4 (3)
CBA = Controlled before-and-after study
* Data as reported in these two papers. Tests of statistical significance were not reported.
Table 5. Additional results from non-randomized studies for prevalence of parasitaemia
Out-
come
Study
ID
Study
design
Age
group
Detail Number with parasitaemia/total number sampled
(percentage)
Com-
ment
Home- or community-based
programmes
Control area
Baseline Follow-
up
Differ-
ence
Baseline Follow-
up
Differ-
ence
Para-
sitaemia
Delacol-
lette
1996
CBA All ages Any par-
a-
sitaemia
87/255
(34.1%)
16/229
(7.0%)
Rate Ra-
tio1 4.9
(3-8.1)
96/254
(37.8)
42/217
(19.3%)
Rate Ra-
tio 2.
0 (1.4-2.
7)
Labelled
as ’crude
parasito-
logical
index’ in
paper.
High
para-
sitaemia
2
34/255
(13.3%)
5/229
(2.2%)
Rate Ra-
tio
6.0 (2.4-
15.3)
44/254
(17.3)
20/217
(9.2%)
Rate Ra-
tio 1.
9 (1.1-3.
1)
Spencer
1987
CBA All ages Dry sea-
son
594/903
(65.7%)
820/
1291
(63.5%)
-2.2% - 363/585
(62.1%)
-
Rainy
season
516/586
(88.1%)
273/361
(75.6%)
-12.5% - 120/159
(75.5%)
-
CBA = Controlled before-and-after study.
1The rate ratio was calculated as: the rate during Feb 1985/ rate during Feb 1987.
2 High parasitaemia defined as > 2,000 asexual forms of P. falciparum per mm3 of blood.
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Table 6. Summary of results for trials comparing RDT diagnosis versus clinical diagnosis
Outcome Study ID
Study design Number of episodes treated/Total
number of episodes
(%)
Relative effect*
(95% CI) Comment
RDT diagnosis Clinical diagno-
sis
Mortality Yeboah-Antwi
2010
Cluster RCT 2/1017
(0.2%)
1/2108
(0.04%)
- The causes
of death were not
determined.
Mubi 2011 Cluster RCT 3/1457
(0.2%)
1/1473
(0.06%)
- Malaria was con-
firmed as the
cause of death in
one patient from
each group
Hospitalization Yeboah-Antwi
2010
Cluster RCT 4/1017
(0.4%)
14/2108
(0.7%)
RR 0.25
(0.04 to 1.50)
Referrals for
further care
Mubi 2011 Cluster RCT 104/1457
(7.1%)
49/1473
(3.3%)
RR 1.89
(1.35 to 2.65)
Severe malaria Yeboah-Antwi
2010
Cluster RCT - - - Not reported.
Mubi 2011 Cluster RCT 1/1457
(0.06%)
1/1473
(0.06%)
- Both
of these children
were given ACT
and referred for
further care. Both
died
Treatment fail-
ure on day 7
Yeboah-Antwi
2010
Cluster RCT 95/1017
(9.3%)
211/2108
(10.0%)
RR 0.68
(0.39 to 1.19)
Defined as
continued symp-
toms, need for
additional treat-
ment, death or
hospitalization
Mubi 2011 Cluster RCT 94/1411
(6.7%)
40/1458
(2.7%)
RR 2.15
(1.50 to 3.09)
Defined as in-
complete recov-
ery.
Treatment with
an appropriate
antimalarial
Yeboah-Antwi
2010
Cluster RCT 265/963
(27.5%)
2066/2084
(99.1%)
RR 0.23
(0.14 to 0.38)
The proportion
of positive RDT
results was 271/
975 (27.8%).
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Table 6. Summary of results for trials comparing RDT diagnosis versus clinical diagnosis (Continued)
Mubi 2011 Cluster RCT 775/1457
(53.2%)
1422/1473
(96.5%)
RR 0.54
(0.46 to 0.62)
The proportion
of positive RDT
results was 733/
1457 (50.3%).
Negative RDT
tests given anti-
malarials
Yeboah-Antwi
2010
Cluster RCT 3/704
(0.4%)
- - The
parents of five ad-
ditional children
with nega-
tive RDT sought
ACT elsewhere
Mubi 2011 Cluster RCT 42/722
(5.8%)
- -
Pos-
itive RDT tests
not given anti-
malarials
Yeboah-Antwi
2010
Cluster RCT - - - None reported.
Mubi 2011 Cluster RCT 2/733
(0.3%)
- - Both were fully
recovered at day
7.
* Relative effects were adjusted for clustering by the study authors. Mubi 2011 presented results as cluster adjusted odds ratio (OR)
which have been converted to risk ratio (RR) using the formula: RR=OR/(1-ACR(1-OR) where ACR = the Assumed Risk in the
control group.
RCT = randomized controlled trial, RDT = rapid diagnostic test, ACT = artemisinin-based combination therapy, CI = confidence
interval
A P P E N D I C E S
Appendix 1. Search strategy
Search set Search terms to be used for all databases:
1 malaria
2 Child*
3 Infant*
4 Paediatr*
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(Continued)
5 Pediatr*
6 Toddler*
7 2 or 3 or 4 or 5 or 6
8 Home-base*
9 Homebase*
10 Community-based
11 Presumptive treatment*
12 Self-care
13 8 or 9 or 10 or 11 or 12
14 1 and 7 and 13
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